GMR
The Original

PHARMACOGENOMICS IN RARE HEREDITARY DISORDERS: EMERGING STRATEGIES FOR PRECISION AND PERSONALISED THERAPEUTICS

[1]Pichoi Arangham, [2*]Mallesh Mandha, [1]Nang Valentina Hopak

[1]Pharm.D, University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, Punjab, 140413 - India.
[2*]Assistant Professor, University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, Punjab, 140413 - India, Email: dr.malleshmandha@gmail.com

ABSTRACT
Pharmacogenomics is driving a transformative shift in the management of rare hereditary disorders, transitioning clinical care from trial-and-error prescribing to mechanism-based precision dosing. This manuscript explores the integration of high-throughput genomic sequencing, pharmacokinetic modeling, and multi-omic data to navigate the extreme clinical heterogeneity inherent in orphan diseases. We highlight the utility of predictive computational frameworks and artificial intelligence in classifying rare pathogenic variants and identifying actionable therapeutic targets. The deployment of innovative modalities, including structure-based small molecule inhibitors, CRISPR-Cas9 gene editing, and mRNA therapeutics, offers unprecedented potential to restore metabolic function and correct enzymatic deficiencies. Furthermore, patient-derived organoid models and decentralized clinical trials utilizing digital biomarkers are establishing robust ex vivo validation and real-time pharmacodynamic tracking. Despite these clinical and technological advancements, significant systemic barriers impede routine clinical implementation. Key challenges include the interpretation of variants of uncertain significance, systemic data fragmentation, the high cost of specialized infrastructure, and rigid regulatory frameworks that struggle to accommodate iterative, individualized interventions. To overcome these hurdles, we advocate for the establishment of global, decentralized data-sharing consortia utilizing federated learning, alongside the implementation of adaptive licensing and value-based reimbursement models. Ultimately, synthesizing multidimensional omics data with longitudinal real-world evidence will democratize access to personalized therapies, establishing a sustainable blueprint for integrating precision pharmacogenomics into standard clinical care for rare disease populations.

KEYWORDS: Pharmacogenomics, Precision Medicine, Rare Hereditary Disorders, Gene Therapy Therapeutics, Orphan Disease Drug Development

INTRODUCTION
Pharmacogenomics represents a transformative paradigm shift in clinical medicine, leveraging an individual's unique genetic composition to optimize therapeutic efficacy and mitigate adverse drug reactions.(Sadée et al., 2023) In the context of rare hereditary disorders, this field offers a vital framework for navigating the significant challenges posed by clinical heterogeneity and the often limited availability of standardized treatment protocols. (Awwad et al., 2024; Roman, 2025) By integrating high-throughput sequencing data with pharmacokinetic modeling, clinicians can now tailor pharmacological interventions to the specific enzymatic deficiencies characteristic of orphan diseases.(Abbas et al., 2025; Owen et al., 2022; Roman, 2025) This precision approach facilitates the identification of genotype-phenotype correlations, revealing previously unidentified metabolic pathways (Abbas et al., 2025).

Furthermore, the integration of pharmacogenomic profiling into diagnostic pipelines addresses the high inter-individual variability often observed in patients with ultra-rare mutations, shifting the focus from trial-and-error prescribing to biomarker-driven therapeutic stratification. (Dugger et al., 2017) Moreover, the deployment of CRISPR-based functional validation allows for the mechanistic assessment of novel variants of uncertain significance, bridging the gap between genomic identification and clinical actionability.(Fellmann et al., 2016; Marwaha et al., 2022) This approach significantly accelerates drug development in orphan populations by ensuring preclinical models accurately reflect the patient-specific molecular landscape.(Byrne et al., 2017) Consequently, these advancements underscore a transition toward dynamic therapeutic oversight, where longitudinal monitoring molecular markers informs real-time adjustments to dosage regimens. (Byrne et al., 2017)Such precision-based strategies are particularly critical for pediatric populations, where rapid developmental changes in drug metabolism necessitate a more nuanced understanding of age-dependent genetic expression. (Hoshitsuki et al., 2021)

Beyond developmental considerations, the implementation of these methodologies faces systemic hurdles, including the scarcity of longitudinal health data and the inherent complexities of reconciling pharmacogenomic insights with existing pharmacological guidelines. (Pan et al., 2022)Addressing these barriers requires the development of decentralized data-sharing consortia that facilitate the aggregation of multi-omic profiles across global rare disease registries. Furthermore,

these collaborative infrastructures are essential for establishing robust statistical power in studies involving small patient cohorts, thereby validating the clinical utility of personalized interventions. (Johnston et al., 2014; Thompson et al., 2014)

Principles of Precision Medicine

The fundamental tenets of precision medicine rely on the integration of systems biology with clinical informatics to move beyond a one-size-fits-all model of care. (Ahmed, 2020; Beckmann & Lew, 2016) By synthesizing high-dimensional omics data with phenotypic outputs, this approach facilitates the construction of individualized disease models that predict treatment responses with unprecedented granularity. (Werner et al., 2014) This multidimensional synthesis allows for the identification of actionable variants within signaling pathways that govern drug disposition, thereby minimizing the incidence of off-target toxicities in patients with high-risk genetic profiles. (Uzilov et al., 2016) Additionally, the incorporation of advanced machine learning algorithms enables the predictive modeling of rare variant effects on protein structural stability, providing crucial insights into pharmacological chaperone therapy selection. (Tafazoli et al., 2023)

These predictive frameworks further expedite the translation of molecular findings into clinical practice by prioritizing compounds that possess the optimal binding affinity for destabilized mutant proteins. (Grasso et al., 2023) By contextualizing these computational predictions within patient-derived organoid models, researchers can empirically validate the therapeutic rescue of protein function prior to bedside implementation. (Mighell & Lehner, 2025) These ex vivo platforms serve as essential biological conduits, allowing for the high-throughput screening of pharmacological libraries against patient-specific cellular architectures to forecast long-term clinical durability. The subsequent transition toward real-time monitoring via circulating cell-free DNA further refines this approach, enabling clinicians to assess the molecular efficacy of these interventions without the constraints of invasive longitudinal biopsies. (Assaf et al., 2023; Wan et al., 2017; Zhang et al., 2020) These liquid biopsy techniques provide a non-invasive surrogate for tissue-level pharmacodynamic tracking, allowing for the dynamic optimization of dosage regimens as metabolic signatures evolve over the course of treatment. Furthermore, the standardization of these biomarker-driven pipelines is essential for ensuring inter-institutional reproducibility and facilitating the integration of pharmacogenomic insights into regulatory approval processes for orphan drug designations (Roman, 2025). Moreover, the harmonization of electronic health record integration remains a critical prerequisite for embedding these genetic insights into routine clinical decision-support systems. (Chenoweth et al., 2019; Giacomini et al., 2012; Krebs & Milani, 2019; Roman, 2025; Schwarz et al., 2018)

Genetic Basis of Variability

The phenotypic expression of rare hereditary disorders is frequently modulated by polymorphic variants in genes encoding drug-metabolizing enzymes, transporters, and receptors, which dictate the interindividual pharmacokinetic landscape. (Euteneuer et al., 2018) Beyond these primary modifiers, epigenetic modifications and regulatory non-coding variants often exert profound, albeit less understood, control over the transcriptional efficiency of these pharmacogenes. These regulatory mechanisms, including DNA methylation patterns and histone modifications, can create distinct gene-expression signatures that amplify or suppress the functional impact of inherited genetic risk. (Smith et al., 2023) Consequently, investigating these regulatory landscapes requires high-resolution techniques such as single-cell RNA sequencing and chromatin accessibility mapping to disentangle the complex interplay between hereditary architecture and dynamic environmental exposure. (Farh et al., 2014) By integrating these multilevel data streams, researchers can better discern how transient environmental stressors exacerbate underlying genetic susceptibilities, thereby refining the predictive accuracy of therapeutic response models. (Mufford et al., 2017) This comprehensive approach further necessitates the adoption of polygenic risk scoring models that account for the cumulative impact of low-penetrance variants, which often act as phenotypic modifiers in monogenic rare disorders. (Oetjens et al., 2019)

Genomic Architecture

The structural foundation of this architecture is defined by high-density linkage disequilibrium blocks that govern the inheritance of pharmacologically relevant haplotypes. These genomic segments are characterized by significant inter-ethnic heterogeneity, which complicates the extrapolation of pharmacogenomic guidelines across diverse patient populations. (Krebs & Milani, 2019; Lee et al., 2021; Yang et al., 2021) To mitigate these disparities, large-scale genomic initiatives are currently prioritizing the inclusion of underrepresented ancestries to construct more inclusive reference panels. By integrating these expansive datasets, investigators can better characterize the rare structural variations that typically escape detection in standard array-based genotyping. (Ebert et al., 2021; Liao et al., 2023; Marwaha et al., 2022) These high-resolution sequencing strategies, particularly long-read technologies, facilitate the resolution of complex genomic rearrangements and copy number variations that frequently underpin the pathogenesis of orphan diseases. (Marwaha et al., 2022; Mastrorosa et al., 2023) Furthermore, the elucidation of these architectural complexities is critical for identifying potential therapeutic targets within non-coding regulatory regions that have traditionally been overlooked in pharmacogenomic screening. Such structural insights are instrumental in mapping the functional impact of deep intronic mutations that disrupt normal splicing patterns and contribute to variable drug response phenotypes. (Recinos et al., 2024; Zhou et al., 2018) Integrating these structural data into comprehensive genotype-phenotype maps allows for the reclassification of variants of uncertain significance, thereby enhancing the diagnostic yield for patients whose clinical presentation remains genetically elusive. (Caswell et al., 2022; Cutting, 2014; Dugger et al., 2017)

Rare Variant Identification

The systematic identification of rare pathogenic alleles relies heavily on the implementation of high-throughput exome and genome sequencing pipelines, which allow the prioritization of low-frequency variants with high predicted functional

impact. (Bomba et al., 2017) By leveraging machine learning algorithms trained on extensive clinical datasets, these pipelines can effectively distinguish between benign passenger mutations and causal variants that fundamentally alter drug metabolism or receptor sensitivity. (Malone et al., 2020) Additionally, integrating protein-ligand docking simulations allows researchers to quantify the reduced binding affinity resulting from these conformational changes, providing a mechanistic basis for tailoring therapeutic concentrations to individual protein variants. (Bello & Bandala, 2023; McCoy et al., 2019; Silva et al., 2022) Future advancements in this domain will likely leverage real-time therapeutic drug monitoring coupled with AI-driven predictive modeling to adjust dosages dynamically in response to metabolic shifts. (Alowais et al., 2023; Lauschke & Ingelman-Sundberg, 2026; Taherdoost & Ghofrani, 2024)

Therapeutic Intervention Strategies

The clinical translation of pharmacogenomic findings into actionable therapeutic interventions requires a paradigm shift from reactive symptom management to mechanism-based precision dosing. This transition necessitates the development of integrated clinical decision support systems capable of processing real-time omics data to provide actionable, patient-specific dosing recommendations at the point of care. (Ahmed, 2020; Minichmayr et al., 2024; Sayadi et al., 2025) Furthermore, the implementation of pharmacogenomic-informed treatment requires robust regulatory frameworks and standardized clinical guidelines to ensure the equitable deployment of targeted therapies across diverse healthcare settings. To facilitate this integration, multi-disciplinary molecular tumor boards are increasingly essential for interpreting complex pharmacogenomic landscapes, ensuring that findings translate seamlessly into personalized clinical protocols. (Kato et al., 2020; Malone et al., 2020; McLeod, 2013; Schwaederlé et al., 2014) Furthermore, the deployment of gene-editing technologies such as CRISPR-Cas9 offers a nascent, curative potential to correct metabolic enzyme deficiencies directly, potentially bypassing the need for chronic, dose-optimized pharmaceutical reliance.

Additionally, the emergence of antisense oligonucleotide-mediated splicing modulation represents a critical frontier for addressing gain-of-function variants that were previously considered undruggable. Complementary to these genetic interventions, mRNA-based therapeutic platforms provide a versatile mechanism for transiently compensating for deficient enzymatic activity, thereby offering a modular approach to restoring homeostatic drug metabolism in patients with refractory metabolic disorders. The ongoing shift toward these bespoke therapeutic modalities underscores the necessity of establishing standardized longitudinal registries to track long-term clinical efficacy and safety profiles. (Bulaklak & Gersbach, 2020; Fischbach et al., 2013; Musunuru et al., 2025; Najimi et al., 2016; Pankowicz et al., 2016; Teng et al., 2024) Moreover, the integration of patient-derived organoid models serves as a pivotal bridge, enabling the empirical validation of pharmacological responses in an *ex vivo* setting prior to initiating clinical exposure. These preclinical validation platforms are further bolstered by the integration of single-cell multi-omics, which characterizes cellular heterogeneity and potential off-target effects at an unprecedented resolution. (Horváth et al., 2016; Sande et al., 2023; Zushin et al., 2023)Consequently, the convergence of high-fidelity longitudinal data with predictive computational modeling facilitates the realization of a truly iterative therapeutic loop, continuously refining treatment regimens based on real-world pharmacodynamic outcomes.

This data-driven cycle ensures that emerging insights from long-term surveillance are systematically incorporated into predictive models, ultimately refining the therapeutic window for populations with limited historical treatment data. (Lu et al., 2021; Terranova et al., 2021; Tosca et al., 2024)Establishing international data-sharing consortia is critical to overcome the challenges posed by low patient prevalence, ensuring that genotype-phenotype correlations are statistically robust across global cohorts. By standardizing phenotypic definitions and diagnostic nomenclature across these networks, researchers can enhance the portability of precision medicine protocols, reducing the fragmentation currently hindering rare disease drug development. Furthermore, fostering collaborative engagement with patient advocacy groups ensures that the evolution of these therapeutic frameworks remains aligned with the lived experiences and prioritized health outcomes of the rare disease community. Ultimately, this synergistic model of precision pharmacogenomics establishes a blueprint for sustainable drug development, bridging the gap between molecular discovery and accessible, personalized clinical care. (Claw et al., 2024; Kosuru et al., 2024; Lakshmi et al., 2025; Lauschke & Ingelman-Sundberg, 2026; Liu et al., 2026; Roman, 2025)

Targeted Small Molecules

Small molecule inhibitors are increasingly tailored to address the distinct structural consequences of pathogenic missense variants, particularly those that destabilize enzyme folds or disrupt metabolic activation pathways. By employing chemical chaperones that stabilize these misfolded protein conformations, clinicians can restore native catalytic activity, thereby mitigating the systemic metabolic consequences of the underlying hereditary defect. (Ong & Kelly, 2010; Platt, 2017; Sawkar et al., 2002; Tran et al., 2020)Moreover, structure-based drug design now enables the synthesis of highly selective ligands that selectively bind to the mutated catalytic site, compensating for reduced substrate affinity through induced conformational stabilization. Beyond stabilization, the application of allosteric modulators allows for the fine-tuned regulation of enzyme activity, preventing the overcompensation that can lead to hazardous metabolic fluctuations.

These small-molecule strategies are further enhanced by the development of proteolysis-targeting chimeras, which facilitate the selective degradation of toxic, gain-of-function protein aggregates in disorders characterized by protein accumulation. (Burslem & Crews, 2017; Toure & Crews, 2016; Wu et al., 2023; Xie et al., 2023)By leveraging high-throughput screening of chemical libraries against patient-specific protein variants, researchers can now identify lead compounds that specifically rescue these defective physiological processes. (Gosai et al., 2010; Pandey & Nichols, 2011)Furthermore, the integration of pharmacophore modeling and molecular dynamics simulations accelerates the optimization of lead candidates, ensuring that these therapeutic agents exhibit high specificity with minimal off-target

interactions. (Jenwitheesuk et al., 2008; Lee et al., 2014)These advancements in computational design also facilitate the identification of synergistic drug combinations capable of modulating interconnected metabolic pathways to compensate for severe enzymatic dysfunction. (Csermely et al., 2013; Tang & Aittokallio, 2014)This iterative refinement process allows for the precise titration of dosage regimens, significantly reducing the risk of adverse drug events while maximizing the therapeutic index for patients with heterogeneous clinical presentations. (Odendaal et al., 2023)

Concurrently, the utilization of artificial intelligence-driven predictive analytics permits the stratification of patients into high-responder cohorts based on their unique molecular signatures, optimizing the selection of small-molecule interventions before the onset of symptomatic progression. (Dlamini et al., 2020; Liu et al., 2024)Additionally, these predictive frameworks facilitate the design of adaptive clinical trial architectures, allowing for rapid real-time modifications based on emerging pharmacodynamic markers in early-phase cohorts. (Cummings et al., 2019; Xie et al., 2022)This integration of adaptive trial designs not only accelerates the regulatory pathway for orphan drug approval but also ensures that the most efficacious therapeutic candidates are prioritized for rapid clinical translation. (Day & Siu, 2016; Ivy et al., 2010)Furthermore, the transition toward decentralized clinical trials leverages wearable biosensors to capture high-frequency longitudinal data, providing a granular view of therapeutic impact on daily patient metabolic function. (Hartl et al., 2021; Oikonomou & Khera, 2023; Shah et al., 2019)

This real-time monitoring infrastructure enables the continuous adjustment of dosing protocols, effectively transforming episodic clinical assessments into a dynamic, patient-centered therapeutic management paradigm. (Awad et al., 2021; Ferguson et al., 2013; Yang et al., 2025)Such advancements underscore a broader shift toward integrating multi-modal data streams, which allows for the proactive management of long-term disease trajectories. Future research must now prioritize the standardization of these digital biomarkers to ensure clinical validity across diverse regulatory jurisdictions. (Coravos et al., 2019; Powell, 2024; Smokovski et al., 2024)Integrating blockchain-based ledgers for secure, immutable data provenance further strengthens the integrity of these multi-institutional clinical registries, ensuring compliance with international privacy standards during large-scale genomic analyses. Ultimately, the establishment of these decentralized, interoperable infrastructures serves as a foundational pillar for global pharmacogenomic surveillance, enabling a shift from reactive care to a proactive, predictive model of rare disease management. (El-Hussein et al., 2024; Johansson et al., 2024; Rehm et al., 2021; Saunders et al., 2019)

Gene Therapy Applications

Recent breakthroughs in viral and non-viral vector technologies have transitioned gene therapy from a theoretical prospect to a clinical reality for monogenic disorders. Adeno-associated virus platforms, specifically engineered for enhanced tissue tropism, have demonstrated significant efficacy in correcting hepatic and neuromuscular enzymatic deficiencies by enabling sustained transgene expression. (Bulcha et al., 2021; Wang et al., 2024)Parallel advancements in CRISPR-Cas9 genome editing now permit the precise correction of pathogenic variants within the endogenous locus, bypassing the limitations of episomal transgene persistence and potential insertional mutagenesis. Furthermore, base editing and prime editing technologies offer additional precision by enabling nucleotide conversions without necessitating double-strand breaks, thereby substantially reducing the risk of unintended chromosomal rearrangements. (Chehelgerdi et al., 2024; Fiumara et al., 2023)These refinements in gene-editing precision are complemented by cell-specific delivery vehicles, such as lipid nanoparticles or engineered exosomes, which shield genetic cargo from premature immunological clearance while enhancing transduction efficiency.

Moreover, the integration of synthetic promoters and tissue-specific enhancers into these delivery platforms minimizes off-target expression in non-affected tissues, further enhancing the safety profile of these genetic interventions. Complementary advances in high-fidelity Cas nucleases and the utilization of inducible genetic switches further enable the temporal regulation of gene expression, facilitating a safer physiological titration of therapeutic protein levels.(Bulaklak & Gersbach, 2020; Fellmann et al., 2016; Zhuo et al., 2021) Collectively, these innovations mitigate the risk of immune-mediated adverse events, shifting the therapeutic landscape toward permanent, self-regulating gene correction strategies. Despite these technical successes, the transition toward clinical implementation necessitates addressing the inherent immunogenicity of viral capsids and the potential for long-term transgene silencing in rapidly dividing cell populations. (Bulcha et al., 2021; Wang et al., 2024)To address these challenges, current investigations are focusing on the development of synthetic immunological stealth capsids and the incorporation of scaffold/matrix attachment regions to stabilize transgene expression within expanding cellular lineages.

Moreover, the implementation of transient immunosuppressive regimens during the peri-administration phase continues to be evaluated as a critical strategy to dampen innate responses against synthetic delivery systems. In parallel, the investigation of epigenetic silencers and chromatin-modifying agents offers a promising avenue to maintain transgene stability without altering the structural integrity of the genome. (Chehelgerdi et al., 2024; Zulliger et al., 2015)Additionally, the development of encapsulated, biomimetic nanocarriers is currently under exploration to shield therapeutic payloads from circulating antibodies, thereby extending the window of therapeutic efficacy for patients with high baseline neutralizing titers. Simultaneously, the refinement of manufacturing protocols for these sophisticated vectors is essential to overcome current bottlenecks in scalability and cost-effectiveness, ensuring equitable access to personalized genetic therapies across diverse socioeconomic landscapes. (Dowling et al., 2024; Kohn et al., 2023)Establishing robust analytical frameworks for potency assay standardization is the next critical frontier, as it will facilitate rigorous cross-platform comparisons and streamline the global certification of complex biologics.

This regulatory standardization will ultimately foster a harmonized framework for international pharmacovigilance, mitigating the risks associated with rapid clinical adoption of advanced genetic medicinal products. By establishing these rigorous benchmarks, stakeholders can accelerate the translation of preclinical discoveries into standardized clinical

practices that prioritize long-term patient safety and therapeutic durability. Furthermore, the implementation of longitudinal real-world evidence registries will be pivotal in capturing the long-term pharmacodynamic impacts of these interventions, providing the necessary data to refine dosing models iteratively throughout the patient's lifespan. Such systemic data collection also enables the identification of subtle, delayed phenotypic shifts, allowing clinicians to preemptively adjust pharmacological interventions before secondary metabolic complications manifest. (Allegaert & Anker, 2015; Elzagallaai et al., 2023; Germovsek et al., 2018; Koch et al., 2021)Integrating these multifaceted longitudinal insights with multi-omic profiling data further enables the development of digital twins, which simulate individual patient responses to optimize therapeutic titration in real-time. This data-driven approach facilitates the identification of patient-specific pharmacokinetic biomarkers, thereby minimizing the incidence of off-target toxicity while maximizing the overall therapeutic window for complex, multisystem hereditary conditions. (Baek et al., 2024; Dette et al., 2025; Scarpa et al., 2011; Valenzano et al., 2011)

Pharmacokinetic Profiling

Tailored pharmacologic intervention in rare disease contexts often requires the rigorous characterization of drug metabolism and transport mechanisms that are intrinsically altered by underlying genetic defects. Specifically, aberrant expression levels of cytochrome P450 enzymes or ATP-binding cassette transporters, secondary to monogenic mutations, can fundamentally shift the drug-clearance profile and necessitate dynamic dosage adjustments.(Kozyra et al., 2016; Samer et al., 2013; Wilkinson, 2005) Consequently, integrating genotype-informed dosing algorithms into clinical decision support systems is essential to preemptively address these altered metabolic trajectories and mitigate the risk of therapeutic failure or systemic toxicity. Beyond these metabolic considerations, the implementation of pharmacogenetic screening prior to initiating targeted therapies ensures that baseline enzymatic activity is accurately mapped, thereby preventing idiosyncratic adverse drug reactions. Furthermore, the application of population-based pharmacokinetic modeling allows for the refinement of drug dosing in pediatric cohorts, where ontogenic fluctuations in physiological clearance pathways complicate standard therapeutic protocols. (Cock et al., 2010; Elzagallaai et al., 2023; Leeder et al., 2014; Salerno et al., 2018)

These advancements are complemented by the integration of physiologically based pharmacokinetic simulations, which model the complex interplay between genetic polymorphisms and altered physiological parameters to predict systemic exposure in previously underrepresented patient populations. This multidimensional approach ultimately transforms standardized drug labeling into dynamic, patient-centric prescribing guidelines that account for the unique metabolic landscape of rare hereditary conditions. Building on these metabolic considerations, the emerging integration of machine learning algorithms with multi-dimensional phenotype data allows for the early identification of patient-specific adverse response patterns that remain obscured by conventional clinical trials. By leveraging predictive analytics, clinicians can now stratify patients based on their inherent risk profiles for drug-induced organ injury, enabling a transition from reactive monitoring to proactive precision prophylaxis. (Hartl et al., 2021; Mulani et al., 2025; Tao et al., 2026; Zhao et al., 2022)This evolution in clinical strategy underscores the transition toward dynamic therapeutic oversight, where real-time patient monitoring interfaces seamlessly with predictive pharmacological modeling to optimize long-term outcomes. Furthermore, the shift toward decentralized clinical monitoring, supported by wearable biosensors and integrated health informatics, provides a continuous stream of pharmacodynamic data that facilitates the recalibration of therapeutic regimens in ambulatory settings.

This paradigm shift necessitates a robust digital infrastructure capable of synthesizing heterogeneous data streams while maintaining stringent data privacy and interoperability standards across global clinical networks. Moreover, the standardization of these high-fidelity data architectures is indispensable for the widespread implementation of federated learning models, which enable the extraction of insights from isolated, patient-centric datasets without compromising sensitive genetic privacy. Ultimately, these advancements catalyze the democratization of specialized care, ensuring that evidence-based precision medicine is accessible even to patients residing in remote or resource-constrained geographic regions. (Ali et al., 2023; Alvarellos et al., 2023; El-Hussein et al., 2024; Froelicher et al., 2021; Udegbe et al., 2024)Future research must now prioritize the longitudinal validation of these decentralized frameworks to ensure that patient-derived outcomes remain consistent across diverse healthcare environments. Consequently, ongoing collaborative efforts must address the integration of these digital ecosystems with legacy hospital information systems to ensure seamless interoperability and prevent the emergence of technological silos. Moreover, establishing universal data ontologies will be critical to harmonize these diverse digital inputs, facilitating the cross-institutional synthesis required to validate rare disease pharmacogenomic signatures at scale. (Aronson & Rehm, 2015; Denton et al., 2021, 2022; Krebs & Milani, 2019; Lehne et al., 2019)Bridging these disparate information silos will ultimately foster a globalized clinical ecosystem, wherein the collective intelligence from rare disease registries directly informs more agile, regulatory-grade therapeutic guidelines.

Furthermore, the incorporation of patient-reported outcome measures into these centralized repositories will provide essential qualitative depth, bridging the gap between molecular precision and the subjective therapeutic efficacy in rare disease populations. Integrating these holistic metrics will empower clinicians to refine therapeutic goals, aligning pharmacological intervention with the nuanced quality-of-life priorities defined by patients and their families. (Contesse et al., 2019; Lanar et al., 2020; Morel & Cano, 2017)This integration of qualitative patient data with quantitative omics-based markers establishes a comprehensive framework for "N-of-1" clinical trial designs, effectively transforming the rare disease diagnostic journey into a continuous, iterative optimization process. Such methodological adaptability is particularly critical when addressing ultra-rare variants where traditional cohort-based statistical power remains unattainable. (Kaufmann et al., 2018; Lunke et al., 2023; Marwaha et al., 2022)

Clinical Implementation Challenges

Despite the theoretical promise of precision pharmacogenomics, the transition to routine clinical practice is hindered by significant logistical barriers, most notably the high cost and limited availability of specialized genetic testing infrastructure in community-based healthcare settings. (Chenoweth et al., 2019; Miltyk et al., 2022; Roden, 2006; Verma et al., 2022)Moreover, the scarcity of specialized bioinformatics expertise creates a substantial knowledge gap, complicating the interpretation of complex genomic variants for general practitioners lacking direct access to genetic counseling support. Additionally, the current lack of standardized clinical decision support tools often prevents the seamless integration of pharmacogenomic insights into existing electronic health records, resulting in fragmented care pathways. Furthermore, regulatory frameworks remain largely underdeveloped regarding the validation of algorithm-driven prescribing, leaving clinicians to navigate significant liability concerns when applying precision medicine insights derived from non-standardized predictive models. (Carini & Seyhan, 2024; Derraz et al., 2024; Tobias et al., 2023; Udegbe et al., 2024)

To address these systemic shortcomings, health systems must prioritize the development of multidisciplinary precision medicine boards capable of contextualizing pharmacogenomic data within the broader framework of a patient's clinical history and comorbid conditions. Concurrently, academic institutions must spearhead targeted educational initiatives to bridge the burgeoning knowledge gap, ensuring that frontline clinicians possess the foundational proficiency required to interpret complex variant-drug interactions effectively. (Ingelman-Sundberg et al., 2023; Lauschke & Ingelman-Sundberg, 2020; Reisberg et al., 2018)Moreover, incentivizing the integration of pharmacogenomic reporting into automated clinical workflows will alleviate the cognitive burden on providers, fostering an environment where evidence-based recommendations are consistently accessible at the point of care. Finally, the establishment of sustainable reimbursement models for comprehensive genomic sequencing and associated decision-support services is essential to eliminate financial disparities and ensure equitable access to personalized therapeutic interventions, particularly for rare disease cohorts.(Félix et al., 2023; Green & Guyer, 2011; Jobanputra et al., 2024; Marwaha et al., 2022)

Data Interpretation Barriers

The challenge of interpreting genomic variants in the context of rare diseases is exacerbated by the high frequency of variants of uncertain significance, which frequently lack the functional evidence required for actionable clinical decision-making. Furthermore, the lack of standardized functional assays often precludes the definitive classification of these variants, leaving clinicians without clear guidance on how to modulate drug dosages or select therapeutic alternatives. (Gelman et al., 2019; Krebs & Milani, 2019; Nofziger et al., 2019; Zhou et al., 2018)To mitigate this diagnostic impasse, integrating high-throughput, patient-derived induced pluripotent stem cell (iPSC) models offers a promising avenue for validating variant-specific drug responses in a physiologically relevant cellular context. These organoid-based platforms enable iterative, real-time pharmacological screening, effectively bypassing the constraints of traditional in vivo models while simultaneously mitigating the risks of experimental polypharmacy. (Rossi et al., 2018; Singh et al., 2025; Sun et al., 2025)Beyond these cellular models, the implementation of machine learning-driven computational pipelines can accelerate the prioritization of functional characterization efforts by predicting the structural impact of missense mutations on protein-drug binding affinities. By leveraging these structural insights, researchers can prioritize variants likely to disrupt metabolic pathways, thereby narrowing the search space for genotype-phenotype correlations.

This predictive approach is further bolstered by the application of multi-omic data integration, which correlates transcriptomic and proteomic perturbations with specific drug-response profiles, thereby enhancing the resolution of variant-to-function mapping. (Iorio et al., 2016; Sengupta et al., 2018; Yi et al., 2017)Ultimately, the synergy between these predictive models and longitudinal real-world evidence will facilitate a more precise classification of rare variants, transitioning pharmacogenomics from a probabilistic endeavor to a deterministic component of personalized patient care. Furthermore, the refinement of ethical governance frameworks is essential to address the complex privacy concerns inherent in managing high-resolution genomic data alongside sensitive clinical health records. Establishing robust data-sharing consortia through federated learning architectures will allow institutions to pool genomic insights while ensuring patient anonymity and regulatory compliance across diverse jurisdictions. (Bracher-Smith & Escott-Price, 2025; Calvino et al., 2024; Kolobkov et al., 2024)By fostering cross-institutional interoperability, these collaborative networks can harmonize heterogeneous datasets, thereby accelerating the discovery of rare allele-drug interactions that would remain obscured within isolated silos. Consequently, this global aggregation of longitudinal data serves as the foundation for dynamic, evidence-based knowledge bases that continuously evolve alongside emerging genomic research. These advancements in collaborative data infrastructure will ultimately transition precision pharmacogenomics from experimental paradigms to standard, scalable components of global genomic medicine. (Hoffman et al., 2014; Manolio et al., 2015; Thorn et al., 2013)

Building upon this framework, the emergence of decentralized digital health platforms provides the requisite technical infrastructure for secure, patient-centric data stewardship, empowering individuals to contribute their genomic profiles to international research cohorts. This transition toward patient-directed data contribution not only democratizes access to genomic inquiry but also ensures that rare disease registries remain representative of global genetic diversity. By institutionalizing such inclusive data-sharing mechanisms, the pharmacogenomic landscape can proactively mitigate historical biases in genomic research, ensuring that therapeutic algorithms remain robust across diverse ancestral populations. Bridging these systemic gaps necessitates the deployment of standardized, cloud-native bioinformatics pipelines that facilitate real-time regulatory oversight and cross-jurisdictional data harmonization. (Bick et al., 2024; Dunker, 1998; Khan et al., 2025; Walton et al., 2023)

Regulatory Oversight

The current regulatory landscape faces significant challenges in adapting traditional drug approval frameworks to the rapid, iterative nature of variant-specific therapeutic adjustments. Existing guidance often emphasizes static therapeutic labels, which fail to accommodate the dynamic evidence updates required for ultrarare disease management. (Berry et al., 2024; Costa et al., 2025)To bridge this regulatory gap, health authorities must pivot toward adaptive licensing frameworks that prioritize real-time post-market surveillance and iterative evidence generation for precision interventions. Furthermore, the implementation of "n-of-1" clinical trial designs could provide a statistically robust pathway for validating therapeutic efficacy in patients with ultrarare mutations, allowing for the formal integration of individualized dosing regimens into institutional prescribing protocols. (Dugger et al., 2017; Gouda et al., 2023)Such frameworks would necessitate the establishment of modernized regulatory endpoints that account for surrogate biomarker normalization rather than relying exclusively on traditional, population-based morbidity or mortality metrics.

Additionally, the adoption of rolling submission processes for diagnostic validation data would allow regulatory agencies to expedite the approval of companion diagnostics tailored to specific genomic markers. This regulatory evolution must be complemented by the development of dynamic prescribing guidelines that automatically update as new pharmacogenomic data enters the clinical knowledge base. (Angelbello et al., 2018; Crews et al., 2012; McLeod, 2013; Wheeler et al., 2012)These digital clinical decision support systems must prioritize seamless integration within existing electronic health record infrastructures to minimize provider cognitive load and facilitate real-time clinical intervention. Moreover, the successful implementation of these digital support tools hinges on rigorous clinician training programs that emphasize the clinical utility of pharmacogenomic insights over purely theoretical genetic risks. Additionally, the cultivation of a multidisciplinary workforce—comprising genetic counsellors, clinical pharmacologists, and bioinformatics specialists is critical to interpreting complex genetic datasets within the high-pressure environment of bedside care. (Caraballo et al., 2016; Green & Guyer, 2011; Haga et al., 2011; Volpi et al., 2018)Building this specialized workforce necessitates the creation of standardized credentialing pathways to ensure practitioners possess the requisite competency in translating multifaceted genomic reports into actionable therapeutic decisions.

Moreover, the implementation of nationwide genomic literacy initiatives will be pivotal in bridging the gap between cutting-edge computational analysis and evidence-based bedside implementation. Ultimately, the synthesis of these educational mandates and infrastructure improvements will catalyze the transition toward a truly integrated healthcare ecosystem where pharmacogenomic precision becomes a routine facet of clinical practice for patients suffering from rare hereditary disorders. (Elzagallaai et al., 2023; Jobanputra et al., 2024; Ta et al., 2019; Weitzel et al., 2016)Moving forward, future research should focus on the longitudinal evaluation of clinical outcomes associated with these precision interventions to substantiate the long-term cost-effectiveness of pharmacogenomic integration. Such investigations must prioritize health equity metrics to ensure that the economic benefits of personalized medicine are distributed equitably across historically underserved patient populations. Moreover,, establishing international reimbursement models that incentivize the use of high-cost, variant-specific therapies will be essential to sustain the clinical adoption of these targeted interventions within healthcare systems globally. (Amuzu et al., 2025; Bertier et al., 2016; Schmitt et al., 2015)Furthermore, the development of value-based pricing frameworks linked to patient-reported outcome measures will provide the necessary economic impetus to align pharmaceutical innovation with the specific requirements of rare disease patient populations. Integrating these economic strategies with robust data interoperability protocols will ensure that the scalability of precision interventions matches the clinical urgency required by these high-acuity populations. Ultimately, the convergence of these multidisciplinary efforts will facilitate the shift from reactive, trial-and-error prescribing to a proactive, genotype-informed paradigm that significantly improves patient safety and quality of life. (Bielinski et al., 2014; Caraballo et al., 2016; Rasmussen-Torvik et al., 2014; Weitzel et al., 2017)

Future Research Directions

Future investigations must prioritize the development of scalable, AI-driven predictive modeling to anticipate drug-gene interactions for novel variants of uncertain significance. Such computational advancements should be coupled with longitudinal multi-omic integration to elucidate the functional consequences of rare non-coding regulatory elements on drug metabolism. (Ingelman-Sundberg et al., 2018; Krebs & Milani, 2019; Zhou et al., 2018)Simultaneously, expanding the scope of these models to encompass transcriptomic and epigenomic data will enable a more nuanced understanding of how phenotypic plasticity influences therapeutic responses across diverse clinical contexts. Beyond these computational efforts, there is an urgent need to bridge the gap between bench-side molecular characterization and real-world clinical implementation by establishing standardized, patient-derived organoid models that allow for *in vitro* pharmacological screening prior to systemic administration. (Horváth et al., 2016; Kong et al., 2020; Xu et al., 2022)

These personalized organoid-on-a-chip platforms represent a paradigm shift, transitioning from population-averaged pharmacokinetic expectations to individualized dose-response validation that minimizes the risk of adverse drug events in highly sensitive patient cohorts. Furthermore, these preclinical models must be standardized through multi-center validation studies to facilitate their incorporation into formal regulatory submissions and drug development pipelines. Moreover, fostering public-private partnerships will be essential to curate centralized biobanks of patient-derived samples, ensuring that rare disease cohorts remain sufficiently powered for large-scale pharmacogenomic validation. (Bienfait et al., 2021; Delavan et al., 2017; Hingorani et al., 2019)Finally, the implementation of blockchain-based data sharing architectures could provide a secure, transparent mechanism for multi-institutional collaboration, mitigating the challenges of data siloing while maintaining rigorous patient privacy standards.

Furthermore, these decentralized frameworks must be complemented by regulatory sandboxes that allow for the iterative testing of algorithmic diagnostic tools in low-risk clinical environments. (Kelly et al., 2019; Silcox et al., 2024)By

fostering an adaptive regulatory landscape, policymakers can better evaluate the safety and efficacy of these digital solutions before their full-scale deployment in complex clinical settings. In addition, longitudinal surveillance programs should be established to monitor the long-term pharmacodynamic impacts of genotype-guided dosing, ensuring that adaptive algorithms remain calibrated against evolving clinical evidence and emerging real-world data streams. Moreover, the integration of patient-centric digital health platforms will empower individuals to actively participate in their therapeutic journey, fostering a transparent feedback loop between clinical observations and genomic data refinement. (Aronson & Rehm, 2015; Ghazani et al., 2017; Malone et al., 2020; Sosinsky et al., 2024)Lastly, cross-disciplinary harmonization of ethical guidelines will serve to standardize the informed consent process, ensuring that the stewardship of genomic information remains strictly aligned with the evolving privacy expectations of patients within rare disease communities. (Aronson & Rehm, 2015; Bonomi et al., 2020; Gainotti et al., 2016; Green & Guyer, 2011; Rockowitz et al., 2020)

Conflict of Interest: None

Funding: None

Acknowledgements: None

REFERENCES

1. Abbas, M., Parayangat, M., Al-Hamami, M. A., Elshafie, H., Al-Shamri, M. Y. H., & Resmi, R. (2025). Emerging Approaches in Data-Driven Drug Discovery for Rare Diseases. Current Drug Metabolism, 26(8), 561–577. https://doi.org/10.2174/0113892002383220250729100138
2. Ahmed, Z. (2020). Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis. Human Genomics, 14(1). https://doi.org/10.1186/s40246-020-00287-z
3. Ali, A., Al-rimy, B. A. S., Tin, T. T., Altamimi, S., Qasem, S. N., & Saeed, F. (2023). Empowering Precision Medicine: Unlocking Revolutionary Insights through Blockchain-Enabled Federated Learning and Electronic Medical Records. Sensors, 23(17), 7476–7476. https://doi.org/10.3390/s23177476
4. Allegaert, K., & Anker, J. van den. (2015). Neonatal drug therapy: The first frontier of therapeutics for children [Review of Neonatal drug therapy: The first frontier of therapeutics for children]. Clinical Pharmacology & Therapeutics, 98(3), 288–297. Wiley. https://doi.org/10.1002/cpt.166
5. Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A., Almohareb, S. N., Aldairem, A., Alrashed, M., Saleh, K. B., Badreldin, H. A., Yami, M. S. A., Harbi, S. A., & Albekairy, A. (2023). Revolutionizing healthcare: the role of artificial intelligence in clinical practice [Review of Revolutionizing healthcare: the role of artificial intelligence in clinical practice]. BMC Medical Education, 23(1). BioMed Central. https://doi.org/10.1186/s12909-023-04698-z
6. Alvarellos, M. L., Sheppard, H. E., Knarston, I., Davison, C. R., Raine, N., Seeger, T., Prieto, P., & Dunford, M. C. (2023). Democratizing clinical-genomic data: How federated platforms can promote benefits sharing in genomics. Frontiers in Genetics, 13. https://doi.org/10.3389/fgene.2022.1045450
7. Amuzu, S., Xie, A., Bai, X., Pekala, K. R., Pickersgill, N. A., Ma, D., Perea-Chamblee, T., Arora, K., Chatila, W. K., Derkach, A., Shen, R., Frampton, G. M., Berger, M. F., Schultz, N., Newberg, J. Y., & Carrot-Zhang, J. (2025). Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers. Nature Genetics. https://doi.org/10.1038/s41588-025-02371-3
8. Angelbello, A. J., Chen, J. L., Childs-Disney, J. L., Zhang, P., Wang, Z.-F., & Disney, M. D. (2018). Using Genome Sequence to Enable the Design of Medicines and Chemical Probes [Review of Using Genome Sequence to Enable the Design of Medicines and Chemical Probes]. Chemical Reviews, 118(4), 1599–1663. American Chemical Society. https://doi.org/10.1021/acs.chemrev.7b00504
9. Aronson, S., & Rehm, H. L. (2015). Building the foundation for genomics in precision medicine [Review of Building the foundation for genomics in precision medicine]. Nature, 526(7573), 336–342. Nature Portfolio. https://doi.org/10.1038/nature15816
10. Assaf, Z. J., Zou, W., Fine, A. D., Socinski, M. A., Young, A., Lipson, D., Freidin, J. F., Kennedy, M., Polisecki, E., Nishio, M., Fabrizio, D., Oxnard, G. R., Cummings, C., Rode, A., Reck, M., Patil, N. S., Lee, M., Shames, D. S., & Schulze, K. (2023). A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nature Medicine, 29(4), 859–868. https://doi.org/10.1038/s41591-023-02226-6
11. Awad, A., Trenfield, S. J., Pollard, T. D., Ong, J. J., Elbadawi, M., McCoubrey, L. E., Goyanes, Á., Gaisford, S., & Basit, A. W. (2021). Connected healthcare: Improving patient care using digital health technologies [Review of Connected healthcare: Improving patient care using digital health technologies]. Advanced Drug Delivery Reviews, 178, 113958–113958. Elsevier BV. https://doi.org/10.1016/j.addr.2021.113958
12. Awwad, O., Ahram, M., Coperchini, F., & Jalil, M. A. (2024). Editorial: Precision medicine: recent advances, current challenges and future perspectives. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1439276
13. Baek, R., Coughlan, K. A., Jiang, L., Liang, M., Ci, L., Singh, H., Zhang, H., Kaushal, N., Rajlic, I. L., Van, L., Dimen, R., Cavedon, A., Yin, L., Rice, L., Frassetto, A., Guey, L. T., Finn, P. F., & Martini, P. G. V. (2024). Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-47460-9

14. Beckmann, J., & Lew, D. (2016). Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities [Review of Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities]. Genome Medicine, 8(1). BioMed Central. https://doi.org/10.1186/s13073-016-0388-7
15. Bello, M., & Bandala, C. (2023). Evaluating the ability of end-point methods to predict the binding affinity tendency of protein kinase inhibitors. RSC Advances, 13(36), 25118–25128. https://doi.org/10.1039/d3ra04916g
16. Berry, D. J., Donigan, K., Kahlman, L., Long, J. M., Markus, C., & McCombs, C. K. (2024). Optimizing regulatory frameworks for gene therapies in rare diseases: Challenges and solutions. PubMed Central, 32(4), 101386–101386. https://doi.org/10.1016/j.omtm.2024.101386
17. Bertier, G., Carrot-Zhang, J., Ragoussis, V., & Joly, Y. (2016). Integrating precision cancer medicine into healthcare—policy, practice, and research challenges. Genome Medicine, 8(1). https://doi.org/10.1186/s13073-016-0362-4
18. Bick, A. G., Metcalf, G., Mayo, K., Lichtenstein, L., Rura, S., Carroll, R. J., Musick, A., Linder, J. E., Jordan, I. K., Nagar, S. D., Sharma, S., Meller, R., Basford, M., Boerwinkle, E., Cicek, M., Doheny, K. F., Eichler, E. E., Gabriel, S., Gibbs, R. A., … Dillon, M. K. (2024). Genomic data in the All of Us Research Program. Nature, 627(8003), 340–346. https://doi.org/10.1038/s41586-023-06957-x
19. Bielinski, S. J., Olson, J. E., Pathak, J., Weinshilboum, R. M., Wang, L., Lyke, K., Ryu, E., Targonski, P. V., Norstrand, M. D. V., Hathcock, M., Takahashi, P. Y., McCormick, J. B., Johnson, K. J., Maschke, K. J., Vitek, C. R. R., Ellingson, M. S., Wieben, E. D., Farrugia, G., Morrisette, J. A., … Kullo, I. J. (2014). Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Time—Using Genomic Data to Individualize Treatment Protocol. Mayo Clinic Proceedings, 89(1), 25–33. https://doi.org/10.1016/j.mayocp.2013.10.021
20. Bienfait, K., Chhibber, A., Marshall, J., Armstrong, M., Cox, C., Shaw, P., & Paulding, C. (2021). Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG) [Review of Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG)]. Human Genetics, 141(6), 1165–1173. Springer Science+Business Media. https://doi.org/10.1007/s00439-021-02282-3
21. Bomba, L., Walter, K., Soranzo, N., Bomba, L., Walter, K., & Soranzo, N. (2017). The impact of rare and low-frequency genetic variants in common disease [Review of The impact of rare and low-frequency genetic variants in common disease]. Genome Biology, 18(1), 77–77. BioMed Central. https://doi.org/10.1186/s13059-017-1212-4
22. Bonomi, L., Huang, Y., & Ohno-Machado, L. (2020). Privacy challenges and research opportunities for genomic data sharing [Review of Privacy challenges and research opportunities for genomic data sharing]. Nature Genetics, 52(7), 646–654. Nature Portfolio. https://doi.org/10.1038/s41588-020-0651-0
23. Bracher-Smith, M., & Escott-Price, V. (2025). Decoding the genomic symphony: unravelling brain disorders through data integration and machine learning. Molecular Psychiatry. https://doi.org/10.1038/s41380-025-03330-4
24. Bulaklak, K., & Gersbach, C. A. (2020). The once and future gene therapy. Nature Communications, 11(1). https://doi.org/10.1038/s41467-020-19505-2
25. Bulcha, J., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021). Viral vector platforms within the gene therapy landscape [Review of Viral vector platforms within the gene therapy landscape]. Signal Transduction and Targeted Therapy, 6(1). Springer Nature. https://doi.org/10.1038/s41392-021-00487-6
26. Burslem, G. M., & Crews, C. M. (2017). Small-Molecule Modulation of Protein Homeostasis. Chemical Reviews, 117(17), 11269–11301. https://doi.org/10.1021/acs.chemrev.7b00077
27. Byrne, A. T., Alférez, D., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budínská, E., Caldas, C., Chang, D. K., Clarke, R. B., Clevers, H., Coukos, G., Dangles-Marie, V., Eckhardt, S. G., González-Suárez, E., Hermans, E., Hidalgo, M., Jarzabek, M. A., … Trusolino, L. (2017). Interrogating open issues in cancer precision medicine with patient-derived xenografts [Review of Interrogating open issues in cancer precision medicine with patient-derived xenografts]. Nature Reviews. Cancer, 17(4), 254–268. Nature Portfolio. https://doi.org/10.1038/nrc.2016.140
28. Calvino, G., Peconi, C., Strafella, C., Trastulli, G., Megalizzi, D., Andreucci, S., Cascella, R., Caltagirone, C., Zampatti, S., & Giardina, E. (2024). Federated Learning: Breaking Down Barriers in Global Genomic Research. Genes, 15(12), 1650–1650. https://doi.org/10.3390/genes15121650
29. Caraballo, P. J., Hodge, L. S., Bielinski, S. J., Stewart, A. K., Farrugia, G., Schultz, C. G., Rohrer-Vitek, C. R., Olson, J. E., Sauver, J. L. St., Roger, V. L., Parkulo, M. A., Kullo, I. J., Nicholson, W. T., Elliott, M. A., Black, J. L., & Weinshilboum, R. M. (2016). Multidisciplinary model to implement pharmacogenomics at the point of care. Genetics in Medicine, 19(4), 421–429. https://doi.org/10.1038/gim.2016.120
30. Carini, C., & Seyhan, A. A. (2024). Tribulations and future opportunities for artificial intelligence in precision medicine [Review of Tribulations and future opportunities for artificial intelligence in precision medicine]. Journal of Translational Medicine, 22(1). BioMed Central. https://doi.org/10.1186/s12967-024-05067-0
31. Caswell, R., Gunning, A. C., Owens, M., Ellard, S., & Wright, C. F. (2022). Assessing the clinical utility of protein structural analysis in genomic variant classification: experiences from a diagnostic laboratory. Genome Medicine, 14(1). https://doi.org/10.1186/s13073-022-01082-2
32. Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024). Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Molecular Cancer, 23(1). https://doi.org/10.1186/s12943-023-01925-5

33. Chenoweth, M. J., Giacomini, K. M., Pirmohamed, M., Hill, S. L., Schaik, R. H. N. van, Schwab, M., Shuldiner, A. R., Relling, M. V., & Tyndale, R. F. (2019). Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. Clinical Pharmacology & Therapeutics, 107(1), 57–61. https://doi.org/10.1002/cpt.1664
34. Claw, K. G., Dorr, C. R., & Woodahl, E. L. (2024). Implementing community-engaged pharmacogenomics in Indigenous communities. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-45032-5
35. Cock, R. F. W. D., Piana, C., Krekels, E. H. J., Danhof, M., Allegaert, K., & Knibbe, C. A. J. (2010). The role of population PK–PD modelling in paediatric clinical research [Review of The role of population PK–PD modelling in paediatric clinical research]. European Journal of Clinical Pharmacology, 67, 5–16. Springer Science+Business Media. https://doi.org/10.1007/s00228-009-0782-9
36. Contesse, M. G., Valentine, J., Wall, T., & Leffler, M. (2019). The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview [Review of The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview]. Advances in Therapy, 36(5), 997–1010. Adis, Springer Healthcare. https://doi.org/10.1007/s12325-019-00920-x
37. Coravos, A., Khozin, S., & Mandl, K. D. (2019). Developing and adopting safe and effective digital biomarkers to improve patient outcomes. Npj Digital Medicine, 2(1). https://doi.org/10.1038/s41746-019-0090-4
38. Costa, E., Ajith, V., Khaldi, A., Isgrò, A., Lee, K. J., Luigetti, R., Pasmooij, A. M. G., Stoyanova-Beninska, V., Trachsel, E., Vaillancourt, J., & Thirstrup, S. (2025). Addressing global regulatory challenges in rare disease drug development. Drug Discovery Today, 30(10), 104462–104462. https://doi.org/10.1016/j.drudis.2025.104462
39. Crews, K. R., Hicks, J. K., Pui, C.-H., Relling, M. V., & Evans, W. E. (2012). Pharmacogenomics and Individualized Medicine: Translating Science Into Practice. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2012.120
40. Csermely, P., Korcsmáros, T., Kiss, H., London, G., & Nussinov, R. (2013). Structure and dynamics of molecular networks: A novel paradigm of drug discovery [Review of Structure and dynamics of molecular networks: A novel paradigm of drug discovery]. Pharmacology & Therapeutics, 138(3), 333–408. Elsevier BV. https://doi.org/10.1016/j.pharmthera.2013.01.016
41. Cummings, J. L., Feldman, H., & Scheltens, P. (2019). The “rights” of precision drug development for Alzheimer’s disease [Review of The “rights” of precision drug development for Alzheimer’s disease]. Alzheimer s Research & Therapy, 11(1). BioMed Central. https://doi.org/10.1186/s13195-019-0529-5
42. Cutting, G. R. (2014). Cystic fibrosis genetics: from molecular understanding to clinical application [Review of Cystic fibrosis genetics: from molecular understanding to clinical application]. Nature Reviews Genetics, 16(1), 45–56. Nature Portfolio. https://doi.org/10.1038/nrg3849
43. Day, D., & Siu, L. L. (2016). Approaches to modernize the combination drug development paradigm [Review of Approaches to modernize the combination drug development paradigm]. Genome Medicine, 8(1). BioMed Central. https://doi.org/10.1186/s13073-016-0369-x
44. Delavan, B., Roberts, R., Huang, R., Bao, W., Tong, W., & Liu, Z. (2017). Computational drug repositioning for rare diseases in the era of precision medicine [Review of Computational drug repositioning for rare diseases in the era of precision medicine]. Drug Discovery Today, 23(2), 382–394. Elsevier BV. https://doi.org/10.1016/j.drudis.2017.10.009
45. Denton, N., Molloy, M., Charleston, S., Lipset, C., Hirsch, J., Mulberg, A. E., Howard, P. C., & Marsh, E. D. (2021). Data silos are undermining drug development and failing rare disease patients. Orphanet Journal of Rare Diseases, 16(1). https://doi.org/10.1186/s13023-021-01806-4
46. Denton, N., Mulberg, A. E., Molloy, M., Charleston, S., Fajgenbaum, D. C., Marsh, E. D., & Howard, P. C. (2022). Sharing is caring: a call for a new era of rare disease research and development. Orphanet Journal of Rare Diseases, 17(1). https://doi.org/10.1186/s13023-022-02529-w
47. Derraz, B., Bréda, G., Kaempf, C., Baenke, F., Cotte, F., Reiche, K., Köhl, U., Kather, J. N., Eskenazy, D., & Gilbert, S. (2024). New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology [Review of New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology]. Npj Precision Oncology, 8(1). Nature Portfolio. https://doi.org/10.1038/s41698-024-00517-w
48. Dette, C. M. U., Alberg, V., Rüdesheim, S., Selzer, D., Marok, F. Z., Bragazzi, N. L., Fuhr, L. M., Brunak, S., Pearson, E. R., Zahn, T., Kiritsi, D., Schwab, M., & Lehr, T. (2025). Advancing rare disease therapeutics through digital twins: Opportunities in drug development and precision dosing. Research at the University of Copenhagen (University of Copenhagen), 28, 592–608. https://doi.org/10.1016/j.csbj.2025.11.047
49. Dlamini, Z., Francies, F. Z., Hull, R., & Marima, R. (2020). Artificial intelligence (AI) and big data in cancer and precision oncology. Computational and Structural Biotechnology Journal, 18, 2300–2311. https://doi.org/10.1016/j.csbj.2020.08.019
50. Dowling, J. J., Pirovolakis, T., Devakandan, K., Stosic, A., Pidsadny, M., Nigro, E., Şahin, M., Ebrahimi-Fakhari, D., Messahel, S., Varadarajan, G. S., Greenberg, B., Chen, X., Minassian, B. A., Cohn, R. D., Bönnemann, C. G., & Gray, S. J. (2024). AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient. Nature Medicine, 30(7), 1882–1887. https://doi.org/10.1038/s41591-024-03078-4
51. Dugger, S. A., Platt, A., & Goldstein, D. B. (2017). Drug development in the era of precision medicine [Review of Drug development in the era of precision medicine]. Nature Reviews Drug Discovery, 17(3), 183–196. Nature Portfolio. https://doi.org/10.1038/nrd.2017.226
52. Dunker, A. K. (1998). The pacific symposium on biocomputing. Journal of Molecular Graphics and Modelling, 16, 267–267. https://doi.org/10.1016/s1093-3263(98)80012-0

53. Ebert, P., Audano, P. A., Zhu, Q., Rodríguez–Martín, B., Porubský, D., Bonder, M. J., Sulovari, A., Ebler, J., Zhou, W., Mari, R. S., Yilmaz, F., Zhao, X., Hsieh, P., Lee, J., Kumar, S., Lin, J., Rausch, T., Chen, Y., Ren, J., … Eichler, E. E. (2021). Haplotype-resolved diverse human genomes and integrated analysis of structural variation. Science, 372(6537). https://doi.org/10.1126/science.abf7117
54. El-Hussein, A., Baymuradov, U. K., Phatnani, H., Kwan, J., Sareen, D., Broach, J. R., Simmons, Z., Arcila-Londono, X., Lee, E. B., Deerlin, V. M. V., Shneider, N. A., Fraenkel, E., Ostrow, L. W., Baas, F., Zaitlen, N., Berry, J. D., Malaspina, A., Fratta, P., Cox, G. A., … Gürsoy, G. (2024). A framework for sharing of clinical and genetic data for precision medicine applications. Nature Medicine, 30(12), 3578–3589. https://doi.org/10.1038/s41591-024-03239-5
55. Elzagallaai, A. A., Barker, C., Lewis, T., Cohn, R. D., & Rieder, M. (2023). Advancing Precision Medicine in Paediatrics: Past, present and future. Cambridge Prisms Precision Medicine, 1. https://doi.org/10.1017/pcm.2022.14
56. Euteneuer, J. C., Kamatkar, S., Fukuda, T., Vinks, A. A., & Akinbi, H. T. (2018). Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy [Review of Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy]. The Journal of Clinical Pharmacology, 59(2), 168–176. Wiley. https://doi.org/10.1002/jcph.1315
57. Farh, K. K.-H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W., Beik, S., Shoresh, N., Whitton, H., Ryan, R. J. H., Shishkin, A. A., Hatan, M., Carrasco-Alfonso, M. J., Mayer, D., Luckey, C. J., Patsopoulos, N. A., Jager, P. L. D., Kuchroo, V. K., Epstein, C. B., Daly, M. J., … Bernstein, B. (2014). Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature, 518(7539), 337–343. https://doi.org/10.1038/nature13835
58. Félix, T. M., Souza, C. F. M. de, Oliveira, J. B., Rico-Restrepo, M., Zanoteli, E., Zatz, M., & Giugliani, R. (2023). Challenges and recommendations to increasing the use of exome sequencing and whole genome sequencing for diagnosing rare diseases in Brazil: an expert perspective [Review of Challenges and recommendations to increasing the use of exome sequencing and whole genome sequencing for diagnosing rare diseases in Brazil: an expert perspective]. International Journal for Equity in Health, 22(1). BioMed Central. https://doi.org/10.1186/s12939-022-01809-y
59. Fellmann, C., Gowen, B. G., Lin, P., Doudna, J. A., & Corn, J. E. (2016). Cornerstones of CRISPR–Cas in drug discovery and therapy [Review of Cornerstones of CRISPR–Cas in drug discovery and therapy]. Nature Reviews Drug Discovery, 16(2), 89–100. Nature Portfolio. https://doi.org/10.1038/nrd.2016.238
60. Ferguson, B. S., Hoggarth, D. A., Maliniak, D., Ploense, K. L., White, R. J., Woodward, N., Hsieh, K., Bonham, A. J., Eisenstein, M., Kippin, T. E., Plaxco, K. W., & Soh, H. T. (2013). Real-Time, Aptamer-Based Tracking of Circulating Therapeutic Agents in Living Animals. Science Translational Medicine, 5(213). https://doi.org/10.1126/scitranslmed.3007095
61. Fischbach, M. A., Bluestone, J. A., & Lim, W. A. (2013). Cell-Based Therapeutics: The Next Pillar of Medicine. Science Translational Medicine, 5(179). https://doi.org/10.1126/scitranslmed.3005568
62. Fiumara, M., Ferrari, S., Omer, A., Beretta, S., Albano, L., Canarutto, D., Varesi, A., Gaddoni, C., Brombin, C., Cugnata, F., Zonari, E., Naldini, M. M., Barcella, M., Gentner, B., Merelli, I., & Naldini, L. (2023). Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nature Biotechnology, 42(6), 877–891. https://doi.org/10.1038/s41587-023-01915-4
63. Froelicher, D., Troncoso-Pastoriza, J. R., Raisaro, J. L., Cuendet, M. A., Sousa, J. S., Cho, H., Berger, B., Fellay, J., & Hubaux, J. (2021). Truly privacy-preserving federated analytics for precision medicine with multiparty homomorphic encryption. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-25972-y
64. Gainotti, S., Turner, C., Woods, S., Kole, A., McCormack, P., Lochmüller, H., Rieß, O., Straub, V., Paz, M. P. de la, Taruscio, D., & Mascalzoni, D. (2016). Improving the informed consent process in international collaborative rare disease research: effective consent for effective research. European Journal of Human Genetics, 24(9), 1248–1254. https://doi.org/10.1038/ejhg.2016.2
65. Gelman, H., Dines, J. N., Berg, J. S., Berger, A. H., Brnich, S. E., Hisama, F. M., James, R. G., Rubin, A. F., Shendure, J., Shirts, B. H., Fowler, D. M., & Starita, L. M. (2019). Recommendations for the collection and use of multiplexed functional data for clinical variant interpretation. Genome Medicine, 11(1). https://doi.org/10.1186/s13073-019-0698-7
66. Germovsek, E., Barker, C., Sharland, M., & Standing, J. F. (2018). Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance [Review of Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance]. Clinical Pharmacokinetics, 58(1), 39–52. Adis, Springer Healthcare. https://doi.org/10.1007/s40262-018-0659-0
67. Ghazani, A. A., Oliver, N., Pierre, J. P. St., Garofalo, A., Rainville, I., Hiller, E., Treacy, D. J., Rojas-Rudilla, V., Wood, S., Bair, E. F., Parello, M., Huang, F. W., Giannakis, M., Wilson, F. H., Stover, E. H., Corsello, S. M., Nguyen, T., Rana, H. Q., Church, A. J., … Wagle, N. (2017). Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics in Medicine, 19(7), 787–795. https://doi.org/10.1038/gim.2016.191
68. Giacomini, K. M., Yee, S. W., Ratain, M. J., Weinshilboum, R. M., Kamatani, N., & Nakamura, Y. (2012). Pharmacogenomics and Patient Care: One Size Does Not Fit All [Review of Pharmacogenomics and Patient Care: One Size Does Not Fit All]. Science Translational Medicine, 4(153). American Association for the Advancement of Science. https://doi.org/10.1126/scitranslmed.3003471
69. Gosai, S. J., Kwak, J. H., Luke, C. J., Long, O. S., King, D. E., Kovatch, K. J., Johnston, P. A., Shun, T. Y., Lazo, J. S., Perlmutter, D. H., Silverman, G. A., & Pak, S. C. (2010). Automated High-Content Live Animal Drug Screening Using C. elegans Expressing the Aggregation Prone Serpin α1-antitrypsin Z. PLoS ONE, 5(11). https://doi.org/10.1371/journal.pone.0015460

70. Gouda, M. A., Buschhorn, L., Schneeweiß, A., Wahida, A., & Subbiah, V. (2023). N-of-1 Trials in Cancer Drug Development [Review of N-of-1 Trials in Cancer Drug Development]. Cancer Discovery, 13(6), 1301–1309. American Association for Cancer Research. https://doi.org/10.1158/2159-8290.cd-22-1377
71. Grasso, D., Galderisi, S., Santucci, A., & Bernini, A. (2023). Pharmacological Chaperones and Protein Conformational Diseases: Approaches of Computational Structural Biology. International Journal of Molecular Sciences, 24(6), 5819–5819. https://doi.org/10.3390/ijms24065819
72. Green, E. D., & Guyer, M. S. (2011). Charting a course for genomic medicine from base pairs to bedside. Nature, 470(7333), 204–213. https://doi.org/10.1038/nature09764
73. Haga, S. B., Tindall, G. M., & O'Daniel, J. (2011). Professional Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings. Genetic Testing and Molecular Biomarkers, 16(1), 21–24. https://doi.org/10.1089/gtmb.2011.0045
74. Hartl, D., Luca, V. D., Kostikova, A., Laramie, J. M., Kennedy, S. R., Ferrero, E., Siegel, R. W., Fink, M., Ahmed, S., Millholland, J. M., Schuhmacher, A., Hinder, M., Piali, L., & Roth, A. (2021). Translational precision medicine: an industry perspective [Review of Translational precision medicine: an industry perspective]. Journal of Translational Medicine, 19(1). BioMed Central. https://doi.org/10.1186/s12967-021-02910-6
75. Hingorani, A. D., Kuan, V., Finan, C., Krüger, F., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R. J., Overington, J. P., Hemingway, H., Denaxas, S., Prieto-Merino, D., & Casas, J. P. (2019). Improving the odds of drug development success through human genomics: modelling study. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-54849-w
76. Hoffman, J. M., Haidar, C. E., Wilkinson, M. R., Crews, K. R., Baker, D. K., Kornegay, N. M., Yang, W., Pui, C., Reiss, U. M., Gaur, A. H., Howard, S. C., Evans, W. E., Broeckel, U., & Relling, M. V. (2014). PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics. American Journal of Medical Genetics Part C Seminars in Medical Genetics, 166(1), 45–55. https://doi.org/10.1002/ajmg.c.31391
77. Horváth, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L., Shorte, S., Turcatti, G., Schantz, C. von, & Carragher, N. O. (2016). Screening out irrelevant cell-based models of disease [Review of Screening out irrelevant cell-based models of disease]. Nature Reviews Drug Discovery, 15(11), 751–769. Nature Portfolio. https://doi.org/10.1038/nrd.2016.175
78. Hoshitsuki, K., Fernandez, C. A., & Yang, J. J. (2021). Pharmacogenomics for Drug Dosing in Children: Current Use, Knowledge, and Gaps. The Journal of Clinical Pharmacology, 61. https://doi.org/10.1002/jcph.1891
79. Ingelman-Sundberg, M., Mkrtchian, S., Zhou, Y., & Lauschke, V. M. (2018). Integrating rare genetic variants into pharmacogenetic drug response predictions. Human Genomics, 12(1). https://doi.org/10.1186/s40246-018-0157-3
80. Ingelman-Sundberg, M., Nebert, D. W., & Lauschke, V. M. (2023). Emerging trends in pharmacogenomics: from common variant associations toward comprehensive genomic profiling. Human Genomics, 17(1). https://doi.org/10.1186/s40246-023-00554-9
81. Iorio, F., Knijnenburg, T., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., Cokelaer, T., Greninger, P., Dyk, E. van, Chang, H., Silva, H. de, Heyn, H., Deng, X., Egan, R. K., Liu, Q., … Garnett, M. J. (2016). A Landscape of Pharmacogenomic Interactions in Cancer. Cell, 166(3), 740–754. https://doi.org/10.1016/j.cell.2016.06.017
82. Ivy, S. P., Siu, L. L., Garrett-Mayer, E., & Rubinstein, L. (2010). Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research, 16(6), 1726–1736. https://doi.org/10.1158/1078-0432.ccr-09-1961
83. Jenwitheesuk, E., Horst, J., Rivas, K., VanVoorhis, W. C., & Samudrala, R. (2008). Novel paradigms for drug discovery: computational multitarget screening [Review of Novel paradigms for drug discovery: computational multitarget screening]. Trends in Pharmacological Sciences, 29(2), 62–71. Elsevier BV. https://doi.org/10.1016/j.tips.2007.11.007
84. Jobanputra, V., Schroeder, B. E., Rehm, H. L., Shen, W., Spiteri, E., Nakouzi, G., Taylor, S. L., Marshall, C. R., Meng, L., Kingsmore, S. F., Ellsworth, K. A., Ashley, E. A., & Taft, R. J. (2024). Advancing access to genome sequencing for rare genetic disorders: recent progress and call to action. Npj Genomic Medicine, 9(1). https://doi.org/10.1038/s41525-024-00410-2
85. Johansson, L., Laurie, S., Spalding, D., Gibson, S., Ruvolo, D., Thomas, C., Piscia, D., Andrade, F. de, Been, G., Bijlsma, M., Brunner, H. G., Cimerman, S., Dizjikan, F. Y., Ellwanger, K., Fernández-Callejo, M., Freeberg, M., Geijn, G. van de, Kanninga, R., Maddi, V., … May, P. (2024). An interconnected data infrastructure to support large-scale rare disease research. GigaScience, 13. https://doi.org/10.1093/gigascience/giae058
86. Johnston, L., Thompson, R., Turner, C., Bushby, K., Lochmüller, H., & Straub, V. (2014). The impact of integrated omics technologies for patients with rare diseases. Expert Opinion on Orphan Drugs, 2(11), 1211–1219. https://doi.org/10.1517/21678707.2014.974554
87. Kato, S., Kim, K. H., Lim, H. J., Boichard, A., Nikanjam, M., Weihe, E., Kuo, D. J., Eskander, R. N., Goodman, A. M., Galanina, N., Fanta, P. T., Schwab, R. B., Shatsky, R., Plaxe, S. C., Sharabi, A. B., Stites, E. C., Adashek, J. J., Okamura, R., Lee, S., … Kurzrock, R. (2020). Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications, 11(1). https://doi.org/10.1038/s41467-020-18613-3
88. Kaufmann, P., Pariser, A., & Austin, C. P. (2018). From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research [Review of From

scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research]. Orphanet Journal of Rare Diseases, 13(1). BioMed Central. https://doi.org/10.1186/s13023-018-0936-x
89. Kelly, C., Karthikesalingam, A., Suleyman, M., Corrado, G. S., & King, D. (2019). Key challenges for delivering clinical impact with artificial intelligence. BMC Medicine, 17(1). https://doi.org/10.1186/s12916-019-1426-2
90. Khan, S., Alam, M., Qasim, I., Khan, S., Khan, W., Mamyrbayev, O., Akhmediyarova, A., Мукажанов, Н., & Alibiyeva, Z. (2025). Genetic Diversity and Mutation Frequency Databases in Ethnic Populations: Systematic Review. JMIR Bioinformatics and Biotechnology, 6. https://doi.org/10.2196/69454
91. Koch, G., Steffens, B., Leroux, S., Gotta, V., Schropp, J., Gächter, P., Bachmann, F., Welzel, T., Janner, M., l'Allemand, D., Konrad, D., Szinnai, G., & Pfister, M. (2021). Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study. Journal of Pharmacokinetics and Pharmacodynamics, 48(5), 711–723. https://doi.org/10.1007/s10928-021-09765-w
92. Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023). Successes and challenges in clinical gene therapy. Gene Therapy, 30, 738–746. https://doi.org/10.1038/s41434-023-00390-5
93. Kolobkov, D., Sharma, S. M., Medvedev, A., Lebedev, M., Kosaretskiy, E., & Vakhitov, R. (2024). Efficacy of federated learning on genomic data: a study on the UK Biobank and the 1000 Genomes Project. Frontiers in Big Data, 7. https://doi.org/10.3389/fdata.2024.1266031
94. Kong, J., Lee, H., Kim, D., Han, S. K., Ha, D., Shin, K., & Kim, S. (2020). Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. Nature Communications, 11(1). https://doi.org/10.1038/s41467-020-19313-8
95. Kosuru, S. K., Gandham, S., Siripalli, B. N. L., Annapurna, K., Vinoothna, D., & Vaishnavi, D. (2024). Precision Pharmacogenomics: A Review. Journal of Clinical and Pharmaceutical Research. https://doi.org/10.61427/jcpr.v4.i1.2024.121
96. Kozyra, M., Ingelman-Sundberg, M., & Lauschke, V. M. (2016). Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genetics in Medicine, 19(1), 20–29. https://doi.org/10.1038/gim.2016.33
97. Krebs, K., & Milani, L. (2019). Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good [Review of Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good]. Human Genomics, 13(1). BioMed Central. https://doi.org/10.1186/s40246-019-0229-z
98. Lakshmi, K. N. V. C., Nagarajan, B., Dabburu, K., Roy, C., Shanthi, B., Das, G., Chakraborty, T., Khund-Sayeed, S., Albert, J., & Prabha, K. (2025). Pharmacogenomics for sustainable drug development: A narrative review of precision medicine, green chemistry, and multi-omics innovation. Journal of Applied Pharmaceutical Science. https://doi.org/10.7324/japs.2025.260740
99. Lanar, S., Acquadro, C., Seaton, J., Savre, I., & Arnould, B. (2020). To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases [Review of To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases]. Orphanet Journal of Rare Diseases, 15(1). BioMed Central. https://doi.org/10.1186/s13023-020-01400-0
100. Lauschke, V. M., & Ingelman-Sundberg, M. (2020). Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation [Review of Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation]. Npj Genomic Medicine, 5(1). Nature Portfolio. https://doi.org/10.1038/s41525-020-0119-2
101. Lauschke, V. M., & Ingelman-Sundberg, M. (2026). The evolving landscape of pharmacogenomics: Current achievements and future directions. Pharmacological Reviews, 78(2), 100122–100122. https://doi.org/10.1016/j.pharmr.2026.100122
102. Lee, J., Jo, D., Park, D., Chung, H. Y., & Mattson, M. P. (2014). Adaptive Cellular Stress Pathways as Therapeutic Targets of Dietary Phytochemicals: Focus on the Nervous System [Review of Adaptive Cellular Stress Pathways as Therapeutic Targets of Dietary Phytochemicals: Focus on the Nervous System]. Pharmacological Reviews, 66(3), 815–868. American Society for Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/pr.113.007757
103. Lee, M. van der, Rowell, W. J., Menafra, R., Guchelaar, H., Swen, J. J., & Anvar, S. Y. (2021). Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. The Pharmacogenomics Journal, 22(1), 75–81. https://doi.org/10.1038/s41397-021-00259-z
104. Leeder, J. S., Brown, J. T., & Soden, S. (2014). Individualizing the Use of Medications in Children: Making Goldilocks Happy. Clinical Pharmacology & Therapeutics, 96(3), 304–306. https://doi.org/10.1038/clpt.2014.130
105. Lehne, M., Saß, J., Essenwanger, A., Schepers, J., & Thun, S. (2019). Why digital medicine depends on interoperability [Review of Why digital medicine depends on interoperability]. Npj Digital Medicine, 2(1). Nature Portfolio. https://doi.org/10.1038/s41746-019-0158-1
106. Liao, W., Asri, M., Ebler, J., Doerr, D., Haukness, M., Hickey, G., Lu, S., Lucas, J., Monlong, J., Abel, H., Buonaiuto, S., Chang, X., Cheng, H., Chu, J., Colonna, V., Eizenga, J. M., Feng, X., Fischer, C., Fulton, R. S., … Tricomi, F. F. (2023). A draft human pangenome reference. Nature, 617(7960), 312–324. https://doi.org/10.1038/s41586-023-05896-x
107. Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X. (2024). Exploring treatment options in cancer: Tumor treatment strategies [Review of Exploring treatment options in cancer: Tumor treatment strategies]. Signal Transduction and Targeted Therapy, 9(1). Springer Nature. https://doi.org/10.1038/s41392-024-01856-7
108. Liu, Y., Xia, X., Chen, Y., Yang, H., Chen, X., Cai, L., & Shi, B. (2026). When Rare Is Not Small: Amyotrophic Lateral Sclerosis Initiatives and Therapy. Exploration. https://doi.org/10.1002/exp2.70114

109. Lu, J., Bender, B. C., Jin, J. Y., & Guan, Y. (2021). Deep learning prediction of patient response time course from early data via neural-pharmacokinetic/pharmacodynamic modelling. Nature Machine Intelligence, 3(8), 696–704. https://doi.org/10.1038/s42256-021-00357-4
110. Lunke, S., Bouffler, S. E., Patel, C., Sandaradura, S. A., Wilson, M., Pinner, J., Hunter, M. F., Barnett, C., Wallis, M., Kamien, B., Tan, T. Y., Freckmann, M., Chong, B., Phelan, D., Francis, D., Kassahn, K. S., Ha, T., Gao, S., Arts, P., … Stark, Z. (2023). Integrated multi-omics for rapid rare disease diagnosis on a national scale. Nature Medicine, 29(7), 1681–1691. https://doi.org/10.1038/s41591-023-02401-9
111. Malone, E. R., Oliva, M., Sabatini, P., Stockley, T., & Siu, L. L. (2020). Molecular profiling for precision cancer therapies [Review of Molecular profiling for precision cancer therapies]. Genome Medicine, 12(1). BioMed Central. https://doi.org/10.1186/s13073-019-0703-1
112. Manolio, T. A., Abramowicz, M., Al-Mulla, F., Anderson, W. P., Balling, R., Berger, A. C., Bleyl, S. B., Chakravarti, A., Chantratita, W., Chisholm, R. L., Dissanayake, V. H. W., Dunn, M., Dzau, V. J., Han, B., Hubbard, T., Kolbe, A., Korf, B. R., Kubo, M., Lasko, P., … Ginsburg, G. S. (2015). Global implementation of genomic medicine: We are not alone [Review of Global implementation of genomic medicine: We are not alone]. Science Translational Medicine, 7(290). American Association for the Advancement of Science. https://doi.org/10.1126/scitranslmed.aab0194
113. Marwaha, S., Knowles, J. W., & Ashley, E. A. (2022). A guide for the diagnosis of rare and undiagnosed disease: beyond the exome [Review of A guide for the diagnosis of rare and undiagnosed disease: beyond the exome]. Genome Medicine, 14(1), 23–23. BioMed Central. https://doi.org/10.1186/s13073-022-01026-w
114. Mastrorosa, F., Miller, D. E., & Eichler, E. E. (2023). Applications of long-read sequencing to Mendelian genetics [Review of Applications of long-read sequencing to Mendelian genetics]. Genome Medicine, 15(1). BioMed Central. https://doi.org/10.1186/s13073-023-01194-3
115. McCoy, M., Shivakumar, V. S., Nimmagadda, S., Jafri, M. S., & Madhavan, S. (2019). SNP2SIM: a modular workflow for standardizing molecular simulation and functional analysis of protein variants. BMC Bioinformatics, 20(1). https://doi.org/10.1186/s12859-019-2774-9
116. McLeod, H. L. (2013). Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed [Review of Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed]. Science, 339(6127), 1563–1566. American Association for the Advancement of Science. https://doi.org/10.1126/science.1234139
117. Mighell, T. L., & Lehner, B. (2025). A small molecule stabilizer rescues the surface expression of nearly all missense variants in a GPCR. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-025-01659-6
118. Miltyk, W., Patrinos, G. P., Verstuyft, C., Coenen, M. J. H., & Tafazoli, A. (2022). Editorial: Translation and implementation of pharmacogenomic testing in daily clinical practice: Considering current challenges and future needs. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1053027
119. Minichmayr, I. K., Mizuno, T., Goswami, S., Peck, R., & Polasek, T. M. (2024). Recent Advances Addressing the Challenges of Precision Dosing. Clinical Pharmacology & Therapeutics, 116(3), 527–530. https://doi.org/10.1002/cpt.3365
120. Morel, T., & Cano, S. (2017). Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures [Review of Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures]. Orphanet Journal of Rare Diseases, 12(1). BioMed Central. https://doi.org/10.1186/s13023-017-0718-x
121. Mufford, M. S., Stein, D. J., Dalvie, S., Groenewold, N. A., Thompson, P. M., & Jahanshad, N. (2017). Neuroimaging genomics in psychiatry—a translational approach [Review of Neuroimaging genomics in psychiatry—a translational approach]. Genome Medicine, 9(1). BioMed Central. https://doi.org/10.1186/s13073-017-0496-z
122. Mulani, A. O., Deshmukh, M., Jadhav, V., Chaudhari, K., Mathew, A. A., & Salunkhe, S. S. (2025). Transforming Drug Therapy with Deep Learning: The Future of Personalized Medicine. Drug Research, 75(8), 326–333. https://doi.org/10.1055/a-2682-5167
123. Musunuru, K., Grandinette, S., Wang, X., Hudson, T. R., Briseno, K., Berry, A. M., Hacker, J., Hsu, A., Silverstein, R. A., Hille, L. T., Oğul, A., Robinson-Garvin, N. A., Small, J. C., McCague, S., Burke, S., Wright, C. M., Bick, S. K., Indurthi, V. S. K., Sharma, S., … Ahrens-Nicklas, R. C. (2025). Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. New England Journal of Medicine, 392(22), 2235–2243. https://doi.org/10.1056/nejmoa2504747
124. Najimi, M., Defresne, F., & Sokal, É. (2016). Concise Review: Updated Advances and Current Challenges in Cell Therapy for Inborn Liver Metabolic Defects. Stem Cells Translational Medicine, 5(8), 1117–1125. https://doi.org/10.5966/sctm.2015-0260
125. Nofziger, C., Turner, A., Sangkuhl, K., Whirl-Carrillo, M., Agúndez, J. A. G., Black, J. L., Dunnenberger, H. M., Ruaño, G., Kennedy, M. A., Phillips, M., Hachad, H., Klein, T. E., & Gaedigk, A. (2019). PharmVar GeneFocus: CYP2D6 [Review of PharmVar GeneFocus: CYP2D6]. Clinical Pharmacology & Therapeutics, 107(1), 154–170. Wiley. https://doi.org/10.1002/cpt.1643
126. Odendaal, C., Jager, E. A., Martines, A.-C. M. F., Vieira-Lara, M. A., Huijkman, N., Kiyuna, L. A., Gerding, A., Wolters, J. C., Heiner-Fokkema, R., Eunen, K. van, Derks, T. G. J., & Bakker, B. M. (2023). Personalised modelling of clinical heterogeneity between medium-chain acyl-CoA dehydrogenase patients. BMC Biology, 21(1). https://doi.org/10.1186/s12915-023-01652-9
127. Oetjens, M. T., Kelly, M., Sturm, A. C., Martin, C. L., & Ledbetter, D. H. (2019). Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-12869-0

128. Oikonomou, E. K., & Khera, R. (2023). Machine learning in precision diabetes care and cardiovascular risk prediction [Review of Machine learning in precision diabetes care and cardiovascular risk prediction]. Cardiovascular Diabetology, 22(1). BioMed Central. https://doi.org/10.1186/s12933-023-01985-3
129. Ong, D. S. T., & Kelly, J. W. (2010). Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases [Review of Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases]. Current Opinion in Cell Biology, 23(2), 231–238. Elsevier BV. https://doi.org/10.1016/j.ceb.2010.11.002
130. Owen, M., Lefebvre, S., Hansen, C. H., Kunard, C. M., Dimmock, D., Smith, L. D., Scharer, G., Mardach, R., Willis, M., Feigenbaum, A., Niemi, A., Ding, Y., Kraan, L. V. D., Ellsworth, K. A., Guidugli, L., Lajoie, B. R., McPhail, T. K., Mehtalia, S., Chau, K., … Kingsmore, S. F. (2022). An automated 13.5 hour system for scalable diagnosis and acute management guidance for genetic diseases. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-31446-6
131. Pan, A., Scodellaro, S., Khan, T., Ushcatz, I., Wu, W., Curtis, M., Cohen, E., Cohn, R. D., Hayeems, R. Z., Meyn, M. S., Orkin, J., Otal, J., Reuter, M. S., Walker, S., Scherer, S. W., Marshall, C. R., Cohn, I., & Costain, G. (2022). Pharmacogenetic profiling via genome sequencing in children with medical complexity. Pediatric Research, 93(4), 905–910. https://doi.org/10.1038/s41390-022-02313-3
132. Pandey, U. B., & Nichols, C. D. (2011). Human Disease Models inDrosophila melanogasterand the Role of the Fly in Therapeutic Drug Discovery [Review of Human Disease Models inDrosophila melanogasterand the Role of the Fly in Therapeutic Drug Discovery]. Pharmacological Reviews, 63(2), 411–436. American Society for Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/pr.110.003293
133. Pankowicz, F. P., Barzi, M., Legras, X., Hubert, L., Tian, M., Tomolonis, J., Ravishankar, M., Sun, Q., Yang, D., Borowiak, M., Sumazin, P., Elsea, S. H., Bissig-Choisat, B., & Bissig, K. (2016). Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nature Communications, 7(1). https://doi.org/10.1038/ncomms12642
134. Platt, F. M. (2017). Emptying the stores: lysosomal diseases and therapeutic strategies [Review of Emptying the stores: lysosomal diseases and therapeutic strategies]. Nature Reviews Drug Discovery, 17(2), 133–150. Nature Portfolio. https://doi.org/10.1038/nrd.2017.214
135. Powell, D. (2024). Walk, talk, think, see and feel: harnessing the power of digital biomarkers in healthcare. Npj Digital Medicine, 7(1). https://doi.org/10.1038/s41746-024-01023-w
136. Rasmussen-Torvik, L. J., Stallings, S., Gordon, A., Almoguera, B., Basford, M., Bielinski, S. J., Brautbar, A., Brilliant, M. H., Carrell, D., Connolly, J. J., Crosslin, D. R., Doheny, K. F., Gallego, C. J., Gottesman, O., Kim, D. S., Leppig, K. A., Li, R., Lin, S., Manzi, S., … Denny, J. C. (2014). Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multicenter Pilot for Preemptive Pharmacogenomics in Electronic Health Record Systems. Clinical Pharmacology & Therapeutics, 96(4), 482–489. https://doi.org/10.1038/clpt.2014.137
137. Recinos, Y., Ustianenko, D., Yeh, Y.-T., Wang, X., Jacko, M., Yesantharao, L. V., Wu, Q., & Zhang, C. (2024). CRISPR-dCas13d-based deep screening of proximal and distal splicing-regulatory elements. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-47140-8
138. Rehm, H. L., Page, A., Smith, L., Adams, J., Alterovitz, G., Babb, L., Barkley, M. P., Baudis, M., Beauvais, M. J. S., Beck, T., Beckmann, J., Beltrán, S., Bernick, D. L., Bernier, A., Bonfield, J., Boughtwood, T., Bourque, G., Bowers, S. R., Brookes, A. J., … Birney, E. (2021). GA4GH: International policies and standards for data sharing across genomic research and healthcare. IRIS, 1(2), 100029–100029. https://doi.org/10.1016/j.xgen.2021.100029
139. Reisberg, S., Krebs, K., Lepamets, M., Kals, M., Mägi, R., Metsalu, K., Lauschke, V. M., Vilo, J., & Milani, L. (2018). Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Genetics in Medicine, 21(6), 1345–1354. https://doi.org/10.1038/s41436-018-0337-5
140. Rockowitz, S., LeCompte, N., Carmack, M. M., Quitadamo, A., Wang, L., Park, M., Knight, D., Sexton, E., Smith, L., Sheidley, B. R., Field, M., Holm, I. A., Brownstein, C. A., Agrawal, P. B., Kornetsky, S., Poduri, A., Snapper, S. B., Beggs, A. H., Yu, T. W., … Sliz, P. (2020). Children's rare disease cohorts: an integrative research and clinical genomics initiative. Npj Genomic Medicine, 5(1). https://doi.org/10.1038/s41525-020-0137-0
141. Roden, D. M. (2006). Pharmacogenomics: Challenges and Opportunities [Review of Pharmacogenomics: Challenges and Opportunities]. Annals of Internal Medicine, 145(10), 749–749. American College of Physicians. https://doi.org/10.7326/0003-4819-145-10-200611210-00007
142. Roman, Y. M. (2025). Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics. Pharmacogenomics, 26, 121–128. https://doi.org/10.1080/14622416.2025.2490465
143. Sadée, W., Wang, D., Hartmann, K. E., & Toland, A. E. (2023). Pharmacogenomics: Driving Personalized Medicine. Pharmacological Reviews, 75(4), 789–814. https://doi.org/10.1124/pharmrev.122.000810
144. Salerno, S., Burckart, G. J., Huang, S., & González, D. (2018). Pediatric Drug–Drug Interaction Studies: Barriers and Opportunities. Clinical Pharmacology & Therapeutics, 105(5), 1067–1070. https://doi.org/10.1002/cpt.1234
145. Samer, C., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. (2013). Applications of CYP450 Testing in the Clinical Setting [Review of Applications of CYP450 Testing in the Clinical Setting]. Molecular Diagnosis & Therapy, 17(3), 165–184. Adis, Springer Healthcare. https://doi.org/10.1007/s40291-013-0028-5
146. Sande, B. V. de, Lee, J. S., Mutasa-Gottgens, E., Naughton, B. J., Bacon, W., Manning, J., Wang, Y., Pollard, J., Mendez, M. G., Hill, J., Kumar, N., Cao, X., Chen, X., Khaladkar, M., Wen, J., Leach, A. R., & Ferrán, E. A. (2023). Applications of single-cell RNA sequencing in drug discovery and development. Nature Reviews Drug Discovery, 22(6), 496–520. https://doi.org/10.1038/s41573-023-00688-4
147. Saunders, G., Baudis, M., Becker, R., Beltrán, S., Béroud, C., Birney, E., Brooksbank, C., Brunak, S., Bulcke, M. V. den, Drysdale, R., Capella-Gutiérrez, S., Flicek, P., Florindi, F., Goodhand, P., Gut, M., Heringa, J., Holub, P.,

Hooyberghs, J., Juty, N., … Scollen, S. (2019). Leveraging European infrastructures to access 1 million human genomes by 2022 [Review of Leveraging European infrastructures to access 1 million human genomes by 2022]. Nature Reviews Genetics, 20(11), 693–701. Nature Portfolio. https://doi.org/10.1038/s41576-019-0156-9
148. Sawkar, A. R., Cheng, W., Beutler, E., Wong, C., Balch, W. E., & Kelly, J. W. (2002). Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease. Proceedings of the National Academy of Sciences, 99(24), 15428–15433. https://doi.org/10.1073/pnas.192582899
149. Sayadi, H., Fromage, Y., Labriffe, M., Codde, C., Monchaud, C., Marquet, P., Ponthier, L., & Woillard, J.-B. (2025). Optimized therapeutic drug monitoring: the role of machine learning models. Expert Review of Clinical Pharmacology, 19(1), 17–26. https://doi.org/10.1080/17512433.2025.2611431
150. Scarpa, M., Ceci, A., Tomanin, R., Mincarone, P., & Begley, D. J. (2011). Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases. The EPMA Journal, 2(2), 231–239. https://doi.org/10.1007/s13167-011-0081-2
151. Schmitt, M., Loeb, L. A., & Salk, J. J. (2015). The influence of subclonal resistance mutations on targeted cancer therapy [Review of The influence of subclonal resistance mutations on targeted cancer therapy]. Nature Reviews Clinical Oncology, 13(6), 335–347. Nature Portfolio. https://doi.org/10.1038/nrclinonc.2015.175
152. Schwaederlé, M., Parker, B. A., Schwab, R. B., Fanta, P. T., Boles, S. G., Daniels, G. A., Bazhenova, L., Subramanian, R., Coutinho, A., Ojeda-Fournier, H., Datnow, B., Webster, N. J. G., Lippman, S. M., & Kurzrock, R. (2014). Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience. The Oncologist, 19(6), 631–636. https://doi.org/10.1634/theoncologist.2013-0405
153. Schwarz, U. I., Gulilat, M., & Kim, R. B. (2018). The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics [Review of The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics]. Cold Spring Harbor Perspectives in Medicine, 9(2). Cold Spring Harbor Laboratory Press. https://doi.org/10.1101/cshperspect.a033027
154. Sengupta, S., Sun, S. Q., Huang, K., Oh, C., Bailey, M. H., Varghese, R., Wyczalkowski, M. A., Ning, J., Tripathi, P., McMichael, J. F., Johnson, K. J., Kandoth, C., Welch, J. S., Cynthia, X., Wendl, M. C., Payne, S., Fenyö, D., Townsend, R., DiPersio, J. F., … Ding, L. (2018). Integrative omics analyses broaden treatment targets in human cancer. Genome Medicine, 10(1). https://doi.org/10.1186/s13073-018-0564-z
155. Shah, P., Kendall, F., Khozin, S., Goosen, R., Hu, J., Laramie, J. M., Ringel, M. S., & Schork, N. J. (2019). Artificial intelligence and machine learning in clinical development: a translational perspective [Review of Artificial intelligence and machine learning in clinical development: a translational perspective]. Npj Digital Medicine, 2(1). Nature Portfolio. https://doi.org/10.1038/s41746-019-0148-3
156. Silcox, C., Zimlichmann, E., Huber, K., Rowen, N. P., Saunders, R. S., McClellan, M., Kahn, C. N., Salzberg, C., & Bates, D. W. (2024). The potential for artificial intelligence to transform healthcare: perspectives from international health leaders. Npj Digital Medicine, 7(1). https://doi.org/10.1038/s41746-024-01097-6
157. Silva, G. M. da, Yang, J., Leang, B., Huang, J., Weinreich, D., & Rubenstein, B. M. (2022). Covalent docking and molecular dynamics simulations reveal the specificity-shifting mutations Ala237Arg and Ala237Lys in TEM beta-lactamase. PLoS Computational Biology, 18(6). https://doi.org/10.1371/journal.pcbi.1009944
158. Singh, D., Thakur, A., Rakesh, & Kumar, A. A. (2025). Advancements in Organoid-Based Drug Discovery: Revolutionizing Precision Medicine and Pharmacology. Drug Development Research, 86(4). https://doi.org/10.1002/ddr.70121
159. Smith, D. A., Sadler, M. C., & Altman, R. B. (2023). Promises and challenges in pharmacoepigenetics [Review of Promises and challenges in pharmacoepigenetics]. Cambridge Prisms Precision Medicine, 1. Cambridge University Press. https://doi.org/10.1017/pcm.2023.6
160. Smokovski, I., Steinle, N., Behnke, A., Bhaskar, S., Grech, G., Richter, K., Niklewski, G., Birkenbihl, C., Parini, P., Andrews, R. J., Bauchner, H., & Golubnitschaja, O. (2024). Digital biomarkers: 3PM approach revolutionizing chronic disease management — EPMA 2024 position. The EPMA Journal, 15(2), 149–162. https://doi.org/10.1007/s13167-024-00364-6
161. Sosinsky, A., Ambrose, J. C., Cross, W., Turnbull, C., Henderson, S., Jones, J. L., Hamblin, A., Arumugam, P., Chan, G. C., Chubb, D., Noyvert, B., Mitchell, J., Walker, S., Bowman, K., Pasko, D., Pereira, M. B., Volkova, N., Rueda-Martin, A., Perez-Gil, D., … Murugaesu, N. (2024). Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme. Nature Medicine, 30(1), 279–289. https://doi.org/10.1038/s41591-023-02682-0
162. Sun, J., Chang, W., Li, B., Zhang, X., Deng, Y., Cai, Y., Gu, Z., & Xie, Z. (2025). Organoids pharmacology and toxicology. EngMedicine, 2(3), 100089–100089. https://doi.org/10.1016/j.engmed.2025.100089
163. Ta, R., Cayabyab, M., & Coloso, R. (2019). Precision Medicine: A Call for Increased Pharmacogenomic Education. Personalized Medicine, 16(3), 233–245. https://doi.org/10.2217/pme-2018-0107
164. Tafazoli, A., Mikros, J., Khaghani, F., Alimardani, M., Rafigh, M., Hemmati, M., Siamoglou, S., Golińska, A. K., Kamiński, K., Niemira, M., Miltyk, W., & Patrinos, G. P. (2023). Pharmacovariome scanning using whole pharmacogene resequencing coupled with deep computational analysis and machine learning for clinical pharmacogenomics. Human Genomics, 17(1). https://doi.org/10.1186/s40246-023-00508-1
165. Taherdoost, H., & Ghofrani, A. (2024). AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy. SPIRE - Sciences Po Institutional REpository, 2(5), 643–650. https://doi.org/10.1016/j.ipha.2024.08.005

166. Tang, J., & Aittokallio, T. (2014). Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles [Review of Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles]. Current Pharmaceutical Design, 20(1), 23–36. Bentham Science Publishers. https://doi.org/10.2174/13816128113199990470
167. Tao, L., Li, X., Wu, Y., & Shan, Y. (2026). Editorial: Exploring adverse drug reactions: monitoring, mechanism, intervention, and resolution. Frontiers in Medicine, 13, 1798711–1798711. https://doi.org/10.3389/fmed.2026.1798711
168. Teng, F., Cui, T., Zhou, L., Gao, Q., Zhou, Q., & Li, W. (2024). Programmable synthetic receptors: the next-generation of cell and gene therapies. Signal Transduction and Targeted Therapy, 9(1). https://doi.org/10.1038/s41392-023-01680-5
169. Thompson, R., Johnston, L., Taruscio, D., Monaco, L., Béroud, C., Gut, M., Hansson, M., Hoen, P.-B. A. 't, Patrinos, G. P., Dawkins, H., Ensini, M., Zatloukal, K., Koubi, D., Heslop, E., Paschall, J., Paz, M. P. de la, Robinson, P. N., Bushby, K., & Lochmüller, H. (2014). RD-Connect: An Integrated Platform Connecting Databases, Registries, Biobanks and Clinical Bioinformatics for Rare Disease Research [Review of RD-Connect: An Integrated Platform Connecting Databases, Registries, Biobanks and Clinical Bioinformatics for Rare Disease Research]. Journal of General Internal Medicine, 29, 780–787. Springer Science+Business Media. https://doi.org/10.1007/s11606-014-2908-8
170. Thorn, C. F., Klein, T. E., & Altman, R. B. (2013). PharmGKB: The Pharmacogenomics Knowledge Base. Methods in Molecular Biology, 311–320. https://doi.org/10.1007/978-1-62703-435-7_20
171. Tobias, D. K., Merino, J., Ahmad, A., Aiken, C., Benham, J. L., Bodhini, D., Clark, A. L., Colclough, K., Corcoy, R., Cromer, S. J., Duan, D., Felton, J. L., Francis, E. C., Gillard, P., Gingras, V., Gaillard, R., Haider, E., Hughes, A. E., Iklé, J. M., … Ried-Larsen, M. (2023). Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine [Review of Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine]. Nature Medicine, 29(10), 2438–2457. Nature Portfolio. https://doi.org/10.1038/s41591-023-02502-5
172. Tosca, E. M., Carlo, A. D., Ronchi, D., & Magni, P. (2024). Model-Informed Reinforcement Learning for Enabling Precision Dosing Via Adaptive Dosing. Clinical Pharmacology & Therapeutics, 116(3), 619–636. https://doi.org/10.1002/cpt.3356
173. Toure, M., & Crews, C. M. (2016). Small-Molecule PROTACS: New Approaches to Protein Degradation. Angewandte Chemie International Edition, 55(6), 1966–1973. https://doi.org/10.1002/anie.201507978
174. Tran, M. L., Génisson, Y., Ballereau, S., & Baudoin-Dehoux, C. (2020). Second-Generation Pharmacological Chaperones: Beyond Inhibitors. Molecules, 25(14), 3145–3145. https://doi.org/10.3390/molecules25143145
175. Udegbe, F. C., Ebulue, O. R., Ebulue, C. C., & Ekesiobi, C. S. (2024a). AI'S IMPACT ON PERSONALIZED MEDICINE: TAILORING TREATMENTS FOR IMPROVED HEALTH OUTCOMES. Engineering Science & Technology Journal, 5(4), 1386–1394. https://doi.org/10.51594/estj.v5i4.1040
176. Udegbe, F. C., Ebulue, O. R., Ebulue, C. C., & Ekesiobi, C. S. (2024b). PRECISION MEDICINE AND GENOMICS: A COMPREHENSIVE REVIEW OF IT-ENABLED APPROACHES [Review of PRECISION MEDICINE AND GENOMICS: A COMPREHENSIVE REVIEW OF IT-ENABLED APPROACHES]. International Medical Science Research Journal, 4(4), 509–520. Fair East Publishers. https://doi.org/10.51594/imsrj.v4i4.1053
177. Uzilov, A., Ding, W., Fink, M. Y., Antipin, Y., Brohl, A. S., Davis, C., Lau, C. Y., Pandya, C., Shah, H., Kasai, Y., Powell, J., Micchelli, M., Castellanos, R., Zhang, Z., Linderman, M. D., Kinoshita, Y., Zweig, M., Raustad, K., Cheung, K., … Chen, R. (2016). Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Medicine, 8(1). https://doi.org/10.1186/s13073-016-0313-0
178. Valenzano, K. J., Khanna, R., Powe, A., Boyd, R. E., Lee, G., Flanagan, J. J., & Benjamin, E. R. (2011). Identification and Characterization of Pharmacological Chaperones to Correct Enzyme Deficiencies in Lysosomal Storage Disorders [Review of Identification and Characterization of Pharmacological Chaperones to Correct Enzyme Deficiencies in Lysosomal Storage Disorders]. Assay and Drug Development Technologies, 9(3), 213–235. Mary Ann Liebert, Inc. https://doi.org/10.1089/adt.2011.0370
179. Verma, S. S., Keat, K., Li, B., Hoffecker, G., Risman, M., Sangkuhl, K., Whirl-Carrillo, M., Dudek, S., Verma, A., Klein, T. E., Ritchie, M. D., & Tuteja, S. (2022). Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population. Journal of Translational Medicine, 20(1). https://doi.org/10.1186/s12967-022-03745-5
180. Volpi, S., Bult, C. J., Chisholm, R. L., Deverka, P. A., Ginsburg, G. S., Jacob, H. J., Kasapi, M., McLeod, H. L., Roden, D. M., Williams, M. S., Green, E. D., Rodriguez, L. L., Aronson, S., Cavallari, L. H., Denny, J. C., Dressler, L. G., Johnson, J. A., Klein, T. E., Leeder, J. S., … Relling, M. V. (2018). Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects [Review of Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects]. Clinical Pharmacology & Therapeutics, 103(5), 778–786. Wiley. https://doi.org/10.1002/cpt.1048
181. Walton, N., Nagarajan, R., Wang, C., Sincan, M., Freimuth, R. R., Everman, D. B., Walton, D. C., McGrath, S., Lemas, D. J., Benos, P. V., Alekseyenko, A. V., Song, Q., Uzun, E. D. G., Taylor, C. O., Uzun, A., Person, T. N., Rappoport, N., Zhao, Z., & Williams, M. S. (2023). Enabling the clinical application of artificial intelligence in genomics: a perspective of the AMIA Genomics and Translational Bioinformatics Workgroup. Journal of the American Medical Informatics Association, 31(2), 536–541. https://doi.org/10.1093/jamia/ocad211
182. Wan, J. C. M., Massie, C., García-Corbacho, J., Moulière, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R. D., & Rosenfeld, N. (2017). Liquid biopsies come of age: towards implementation of circulating tumour DNA [Review of Liquid

biopsies come of age: towards implementation of circulating tumour DNA]. Nature Reviews. Cancer, 17(4), 223–238. Nature Portfolio. https://doi.org/10.1038/nrc.2017.7
183. Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024). Adeno-associated virus as a delivery vector for gene therapy of human diseases [Review of Adeno-associated virus as a delivery vector for gene therapy of human diseases]. Signal Transduction and Targeted Therapy, 9(1). Springer Nature. https://doi.org/10.1038/s41392-024-01780-w
184. Weitzel, K., Aquilante, C. L., Johnson, S. G., Kisor, D. F., & Empey, P. E. (2016). Educational strategies to enable expansion of pharmacogenomics-based care [Review of Educational strategies to enable expansion of pharmacogenomics-based care]. American Journal of Health-System Pharmacy, 73(23), 1986–1998. Oxford University Press. https://doi.org/10.2146/ajhp160104
185. Weitzel, K., Cavallari, L. H., & Lesko, L. J. (2017). Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now [Review of Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now]. Pharmaceutical Research, 34(8), 1551–1555. Springer Science+Business Media. https://doi.org/10.1007/s11095-017-2163-x
186. Werner, H. M. J., Mills, G. B., & Ram, P. T. (2014). Cancer Systems Biology: a peek into the future of patient care? [Review of Cancer Systems Biology: a peek into the future of patient care?]. Nature Reviews Clinical Oncology, 11(3), 167–176. Nature Portfolio. https://doi.org/10.1038/nrclinonc.2014.6
187. Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J., & Ratain, M. J. (2012). Cancer pharmacogenomics: strategies and challenges [Review of Cancer pharmacogenomics: strategies and challenges]. Nature Reviews Genetics, 14(1), 23–34. Nature Portfolio. https://doi.org/10.1038/nrg3352
188. Wilkinson, G. (2005). Drug Metabolism and Variability among Patients in Drug Response. New England Journal of Medicine, 352(21), 2211–2221. https://doi.org/10.1056/nejmra032424
189. Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023). Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies [Review of Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies]. Signal Transduction and Targeted Therapy, 8(1). Springer Nature. https://doi.org/10.1038/s41392-023-01439-y
190. Xie, C., Zhuang, X., Niu, Z., Ai, R., Lautrup, S., Zheng, S., Jiang, Y., Han, R., Gupta, T. S., Cao, S., Lagartos-Donate, M. J., Cai, C.-Z., Xie, L., Caponio, D., Wang, W., Schmauck-Medina, T., Zhang, J., Wang, H., Lou, G., … Fang, E. F. (2022). Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow. Nature Biomedical Engineering, 6(1), 76–93. https://doi.org/10.1038/s41551-021-00819-5
191. Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023). Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials [Review of Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials]. Signal Transduction and Targeted Therapy, 8(1). Springer Nature. https://doi.org/10.1038/s41392-023-01589-z
192. Xu, H., Jiao, D., Liu, A., & Wu, K. (2022). Tumor organoids: applications in cancer modeling and potentials in precision medicine [Review of Tumor organoids: applications in cancer modeling and potentials in precision medicine]. Journal of Hematology & Oncology, 15(1). BioMed Central. https://doi.org/10.1186/s13045-022-01278-4
193. Yang, H., Chen, C., Lin, Y., & Chu, S. (2021). Genetic ancestry plays a central role in population pharmacogenomics. Communications Biology, 4(1). https://doi.org/10.1038/s42003-021-01681-6
194. Yang, J., Gong, X., Zheng, Y., Duan, H., Chen, S., Wu, T., Yi, C., Jiang, L., & Haick, H. (2025). Microneedle-based integrated pharmacokinetic and pharmacodynamic evaluation platform for personalized medicine. Nature Communications, 16(1), 6260–6260. https://doi.org/10.1038/s41467-025-61549-9
195. Yi, S. S., Lin, S., Li, Y., Zhao, W., Mills, G. B., & Sahni, N. (2017). Functional variomics and network perturbation: connecting genotype to phenotype in cancer [Review of Functional variomics and network perturbation: connecting genotype to phenotype in cancer]. Nature Reviews Genetics, 18(7), 395–410. Nature Portfolio. https://doi.org/10.1038/nrg.2017.8
196. Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., Heijden, M. S. van der, Segal, N. H., Chaft, J. E., Hembrough, T., Barrett, J. C., & Hellmann, M. D. (2020). Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discovery, 10(12), 1842–1853. https://doi.org/10.1158/2159-8290.cd-20-0047
197. Zhao, C., Jiang, Y., Zhang, X., Zheng, R., Qiu, R., Sun, Y., Zhao, C., & Hong-cai, S. (2022). The prediction approach of drug-induced liver injury: response to the issues of reproducible science of artificial intelligence in real-world applications. Briefings in Bioinformatics, 23(4). https://doi.org/10.1093/bib/bbac196
198. Zhou, Y., Fujikura, K., Mkrtchian, S., & Lauschke, V. M. (2018). Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data [Review of Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data]. Frontiers in Pharmacology, 9. Frontiers Media. https://doi.org/10.3389/fphar.2018.01437
199. Zhuo, C., Zhang, J., Lee, J., Jiao, J., Cheng, D., Liu, L., Kim, H., Tao, Y., & Li, M. (2021). Spatiotemporal control of CRISPR/Cas9 gene editing [Review of Spatiotemporal control of CRISPR/Cas9 gene editing]. Signal Transduction and Targeted Therapy, 6(1). Springer Nature. https://doi.org/10.1038/s41392-021-00645-w
200. Zulliger, R., Conley, S. M., & Naash, M. I. (2015). Non-viral therapeutic approaches to ocular diseases: An overview and future directions [Review of Non-viral therapeutic approaches to ocular diseases: An overview and future directions]. Journal of Controlled Release, 219, 471–487. Elsevier BV. https://doi.org/10.1016/j.jconrel.2015.10.007